<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:00:25Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10800039" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10800039</identifier>
        <datestamp>2024-01-21</datestamp>
        <setSpec>bmcph</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">BMC Public Health</journal-id>
              <journal-id journal-id-type="iso-abbrev">BMC Public Health</journal-id>
              <journal-title-group>
                <journal-title>BMC Public Health</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1471-2458</issn>
              <publisher>
                <publisher-name>BioMed Central</publisher-name>
                <publisher-loc>London</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10800039</article-id>
              <article-id pub-id-type="pmcid">PMC10800039</article-id>
              <article-id pub-id-type="pmc-uid">10800039</article-id>
              <article-id pub-id-type="pmid">38245668</article-id>
              <article-id pub-id-type="pmid">38245668</article-id>
              <article-id pub-id-type="publisher-id">17724</article-id>
              <article-id pub-id-type="doi">10.1186/s12889-024-17724-6</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Study Protocol</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Acceptability, cost-effectiveness, and capacity of a facility-based seasonal influenza vaccination among high-risk groups: a study protocol in selected tertiary care hospitals of Bangladesh</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Hassan</surname>
                    <given-names>Md Zakiul</given-names>
                  </name>
                  <address>
                    <email>zhassan@icddrb.org</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Biswas</surname>
                    <given-names>Md Abdullah Al Jubayer</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rahman</surname>
                    <given-names>Mahbubur</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Shoshi</surname>
                    <given-names>Homayra Rahman</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Pyash</surname>
                    <given-names>Ashrak Shad</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Islam</surname>
                    <given-names>Md Ariful</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Haque</surname>
                    <given-names>Md Azizul</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Parvin</surname>
                    <given-names>Syeda Rukhshana</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hossen</surname>
                    <given-names>Md Tanvir</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hussain</surname>
                    <given-names>Mofakhar</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff7">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rahman</surname>
                    <given-names>Mahmudur</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff8">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Shirin</surname>
                    <given-names>Tahmina</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chowdhury</surname>
                    <given-names>Fahmida</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04vsvr128</institution-id><institution-id institution-id-type="GRID">grid.414142.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 0600 7174</institution-id><institution>Programme for Emerging Infections, Infectious Disease Division, </institution><institution>International Centre for Diarrhoeal Disease Research, </institution></institution-wrap>Bangladesh (icddr,b), Mohakhali, Dhaka, Bangladesh </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/052gg0110</institution-id><institution-id institution-id-type="GRID">grid.4991.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8948</institution-id><institution>Nuffield Department of Clinical Medicine, </institution><institution>University of Oxford, </institution></institution-wrap>Oxford, UK </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.502825.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 0455 1600</institution-id><institution>Institute of Epidemiology, </institution><institution>Disease Control and Research, </institution></institution-wrap>Mohakhali, Dhaka, Bangladesh </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.466907.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 6082 1679</institution-id><institution>The Expanded Programme on Immunization (EPI), </institution><institution>Maternal Neonatal Child and Adolescent Health of the Ministry of Health &amp; Family Welfare of Bangladesh, </institution></institution-wrap>Dhaka, Bangladesh </aff>
                <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02k4h0b10</institution-id><institution-id institution-id-type="GRID">grid.415637.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 5932 2784</institution-id><institution>Department of Medicine, </institution><institution>Rajshahi Medical College, </institution></institution-wrap>Rajshahi, Bangladesh </aff>
                <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05xswp225</institution-id><institution-id institution-id-type="GRID">grid.415209.b</institution-id><institution>Department of Paediatrics, </institution><institution>Khulna Medical College, </institution></institution-wrap>Khulna, Bangladesh </aff>
                <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03dbr7087</institution-id><institution-id institution-id-type="GRID">grid.17063.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2157 2938</institution-id><institution>Institute of Health Policy, Management and Evaluation, </institution><institution>University of Toronto, </institution></institution-wrap>Toronto, Canada </aff>
                <aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00adtdy17</institution-id><institution-id institution-id-type="GRID">grid.507111.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 4662 2163</institution-id><institution>Global Health Development (GHD), </institution><institution>The Eastern Mediterranean Public Health Network (EMPHNET), </institution></institution-wrap>Abdallah Ben Abbas St, Building No. 42, Amman, Jordan </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>20</day>
                <month>1</month>
                <year>2024</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>20</day>
                <month>1</month>
                <year>2024</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2024</year>
              </pub-date>
              <volume>24</volume>
              <elocation-id>242</elocation-id>
              <history>
                <date date-type="received">
                  <day>12</day>
                  <month>9</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>10</day>
                  <month>1</month>
                  <year>2024</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2024</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <sec>
                  <title>Background</title>
                  <p id="Par1">In Bangladesh, seasonal influenza imposes considerable disease and economic burden, especially for those at high-risk of severe disease. The most successful approach for influenza prevention is the administration of a vaccine. Many poor and middle-income nations, including Bangladesh, do not have a national strategy or program in place for seasonal influenza vaccines, despite the World Health Organization’s (WHO) advice to prioritize high-risk populations. Additionally, there is a scarcity of substantial data on the cost-effectiveness of seasonal influenza vaccination in these countries. The aim of our study is to determine acceptability, health beliefs, barriers, and intention of receiving influenza vaccine among high-risk populations, assess the cost-effectiveness of implementing a facility-based seasonal influenza vaccination programme, and investigate the required capacity for a potential seasonal influenza vaccination programme.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p id="Par2">We will undertake this study following STROBE guidelines. We will conduct the study in inpatient and outpatient departments of three selected tertiary-level hospitals leveraging the ongoing hospital-based influenza surveillance (HBIS) platform. The study population will include the WHO-defined four high-risk groups excluding healthcare workers: children six months to eight years, pregnant women, elderly ≥ 60 years, and adults with chronic diseases. We will collect quantitative data on participants’ acceptability, health beliefs, barriers, and vaccination intentions using the health belief model (HBM) from patients meeting the criteria for high-risk populations attending two public tertiary-level hospitals. In one of the two public tertiary-level hospitals, we will arrange an influenza vaccination campaign before the influenza season, where the vaccine will be offered free of cost to high-risk patients, and in the second hospital, vaccination will not be offered. Both the vaccinated and unvaccinated participants will then be followed-up once a month for one year to record any influenza-like illness, hospitalization, and death. Additional data for objective two will be collected from patients with symptoms of influenza-like illness (ILI) and severe acute respiratory infection (SARI) at one public and one private hospital to determine both direct and indirect costs associated with influenza illness. We will estimate the required number of influenza vaccines, safe injections, and total storage volume utilizing secondary data. We will use a deterministic Markov decision-analytic model to estimate the cost-effectiveness of facility-based influenza vaccination in Bangladesh.</p>
                </sec>
                <sec>
                  <title>Discussion</title>
                  <p id="Par3">The results of this study will enable the National Immunization Technical Advisory Group and the Ministry of Health &amp; Family Welfare of Bangladesh to decide what steps to take to develop and implement an influenza vaccination strategy targeting high-risk populations.</p>
                </sec>
                <sec>
                  <title>Trial registration</title>
                  <p id="Par4">The Clinicaltrials.gov registration number is NCT05996549. The registration for the protocol version 2.0 took place in August 2023, with the initial participant being enrolled in March 2022.</p>
                </sec>
              </abstract>
              <kwd-group xml:lang="en">
                <title>Keywords</title>
                <kwd>Seasonal influenza vaccination</kwd>
                <kwd>Vaccination cost-effectiveness</kwd>
                <kwd>High-risk group population</kwd>
                <kwd>Vaccine acceptability</kwd>
                <kwd>Health belief model</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution>US Centers for Disease Control and Prevention (CDC), Atlanta</institution>
                  </funding-source>
                  <award-id>GR-01846</award-id>
                  <award-id>GR-01846</award-id>
                  <award-id>GR-01846</award-id>
                  <award-id>GR-01846</award-id>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© BioMed Central Ltd., part of Springer Nature 2024</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1">
              <title>Background</title>
              <p id="Par5">Globally, Seasonal influenza is a major contributor to morbidity and mortality, resulting in significant health and economic consequences [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR3">3</xref>]. Based on data provided by the World Health Organization (WHO), it is estimated that influenza affects approximately one billion individuals annually [<xref ref-type="bibr" rid="CR4">4</xref>]. Among these cases, 3 to 5 million individuals experience severe illness, resulting in 290,000 to 650,000 annual fatalities [<xref ref-type="bibr" rid="CR4">4</xref>]. Low- and middle-income countries (LMICs) bear a disproportionately higher burden of influenza-related illness in comparison to high-income countries (HICs) [<xref ref-type="bibr" rid="CR5">5</xref>]. Within LMICs, certain demographic groups are particularly vulnerable to experiencing severe illness as a result of influenza [<xref ref-type="bibr" rid="CR5">5</xref>]. These groups include pregnant women, children under the age of five, the elderly, healthcare workers, and adults who have underlying health conditions [<xref ref-type="bibr" rid="CR5">5</xref>]. Previous reports showed that older people were at higher risk of death and hospital admission during flu season [<xref ref-type="bibr" rid="CR6">6</xref>]. The report also found that pregnant women and children were at higher risk of developing pneumonia and requiring hospital admission; the adults with co-morbidity conditions were at risk of hospitalization and intensive care admission during flu seasons [<xref ref-type="bibr" rid="CR6">6</xref>].</p>
              <p id="Par6">To minimize the risk of influenza infection and reduce the severity of the associated illness, the World Health Organization (WHO) recommended in 2012 that persons at high risk of experiencing severe influenza symptoms receive an annual dosage of the influenza vaccine [<xref ref-type="bibr" rid="CR7">7</xref>]. Despite the WHO recommendation of seasonal influenza vaccination prioritizing high-risk groups, 76% of the LMICs, including Bangladesh, lack a national policy/programme on seasonal influenza targeting high-risk groups [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Notably, the WHO African Region (6.3%) and the WHO South-East Asian Region (18%) had the lowest proportions of countries having influenza vaccine policies [<xref ref-type="bibr" rid="CR9">9</xref>].</p>
              <p id="Par7">Moreover, influenza vaccine coverage remains low in LMICs. A systematic review of seasonal influenza vaccine coverage in LMICs revealed considerable variation in vaccination rates across different demographic groups [<xref ref-type="bibr" rid="CR10">10</xref>]. Specifically, among children, the coverage ranged from as low as 2% to as high as 72% in these countries [<xref ref-type="bibr" rid="CR10">10</xref>]. Similarly, the vaccination coverage among the elderly ranged from 10 to 70%, while pregnant women exhibited a range of 0–4% coverage [<xref ref-type="bibr" rid="CR10">10</xref>]. Among healthcare professionals, the vaccination coverage varied from 20 to 56% in the LMICs under study [<xref ref-type="bibr" rid="CR10">10</xref>]. The potential cause for the low vaccination coverage may be attributed to the suboptimal rates of influenza vaccine uptake [<xref ref-type="bibr" rid="CR11">11</xref>–<xref ref-type="bibr" rid="CR14">14</xref>]. Research conducted on populations at high risk for influenza revealed varying rates of influenza vaccine uptake [<xref ref-type="bibr" rid="CR11">11</xref>–<xref ref-type="bibr" rid="CR14">14</xref>]. Specifically, the uptake of the influenza vaccine was observed to be 33.3% among healthcare workers, 5.4% among elderly individuals, 27% among pregnant women, and 33.7% among adults with co-morbid conditions [<xref ref-type="bibr" rid="CR11">11</xref>–<xref ref-type="bibr" rid="CR14">14</xref>].</p>
              <p id="Par8">To identify challenges to promoting influenza vaccinations in LMICs, several studies explored various barriers to influenza vaccination, such as inadequate infrastructures to provide universal vaccination services and insufficient systems for evaluating, procuring, regulating, storing, distributing, monitoring, and administering the vaccine [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Also, the lack of context-specific knowledge on the economic burden of influenza vaccines on high-risk groups, lack of medical socio-behavioral patterns, and socio-economic consequences of influenza have been identified as challenges for promoting influenza vaccinations in LMICs [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>].</p>
              <p id="Par9">In Bangladesh, the influenza-associated mortality rate was estimated at six per 100,000 for under-five children and 41 per 1000,00 for persons &gt; 60 years [<xref ref-type="bibr" rid="CR17">17</xref>]. Also, the rate of hospitalization associated with influenza was estimated to be between 4.4 and 6.7 per 1,000 individuals in the population [<xref ref-type="bibr" rid="CR18">18</xref>]. In contrast, the rate of influenza among outpatients with influenza-like illness (ILI) was estimated to be between 100 and 170 per 1,000 individuals in the population [<xref ref-type="bibr" rid="CR18">18</xref>]. In 2010, approximately 25 million individuals across all age groups sought outpatient medical care for influenza in Bangladesh [<xref ref-type="bibr" rid="CR3">3</xref>]. This resulted in an annual direct expenditure of US$ 108 million specifically attributed to influenza-related outpatient visits [<xref ref-type="bibr" rid="CR3">3</xref>]. Moreover, approximately 30,592 laboratory-confirmed influenza patients of all ages were hospitalized each year, with an estimated annual influenza-associated hospitalization cost of US$ 1.4 million [<xref ref-type="bibr" rid="CR3">3</xref>].</p>
              <p id="Par10">Influenza vaccines are the most reliable method for preventing influenza infection. Unfortunately, Bangladesh does not have a national influenza vaccination program among the WHO-recommended high-risk population [<xref ref-type="bibr" rid="CR19">19</xref>]. The Ministry of Health and Family Welfare (MoH&amp;FW), the Government of the People’s Republic of Bangladesh, provides complimentary influenza vaccinations exclusively to Hajj pilgrims [<xref ref-type="bibr" rid="CR20">20</xref>]. This service is offered in adherence to the obligatory criteria set by the Saudi Government for all individuals participating in the Hajj pilgrimage [<xref ref-type="bibr" rid="CR20">20</xref>]. However, there is a lack of information to drive the MoH&amp;FW policy on influenza vaccinations in high-risk populations.</p>
              <p id="Par11">For reducing the influenza disease burden, influenza vaccination has demonstrated significant efficacy and cost-effectiveness, particularly within populations at high risk of infection [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. The immune responses induced by influenza vaccines are typically specific to the particular viral strain. The presence of antibodies specific to a certain type or subtype of influenza virus typically offers minimal or no immunity against other types or subtypes. Furthermore, such antibodies usually do not protect against antigenic variants of the same virus that emerge due to antigenic drift. Vaccination can potentially induce a “back boost” of antibody titers specifically targeting influenza A(H3N2) viruses in the adult population. Influenza vaccines are administered on an annual basis due to the occurrence of antigenic drift and shift. The efficacy of these vaccines, which typically ranges between 40% and 60%, exhibits considerable variation across different settings and influenza seasons [<xref ref-type="bibr" rid="CR10">10</xref>]. In addition, the findings of a systematic review indicated that out of the 118 studies examined, 22 studies demonstrated that influenza vaccination resulted in cost savings [<xref ref-type="bibr" rid="CR23">23</xref>]. This study’s findings also stated that there were 13 studies reporting cost-effectiveness ratios of $10,000 per outcome, another 13 reporting ratios ranging from $10,000 to $50,000 per outcome, and three reporting ratios equal to or exceeding $50,000 per outcome [<xref ref-type="bibr" rid="CR23">23</xref>]. Although the cost-effectiveness of influenza vaccination has been established, it is necessary to note that the applicability of cost-effectiveness parameters may vary across different countries due to variations in influenza disease profiles, unit costs of vaccination, and health system delivery mechanisms [<xref ref-type="bibr" rid="CR24">24</xref>]. Hence, it is imperative to have country-specific estimates to allocate limited resources effectively.</p>
              <p id="Par12">Bangladesh lacks context-specific data on the acceptability, cost-effectiveness, and vaccination capacity needed for influenza vaccination among the WHO-defined high-risk population, which hinders informed vaccination strategies.</p>
              <sec id="Sec2">
                <title>Objectives</title>
                <p id="Par13">We propose to generate preliminary data on high-risk groups’ health beliefs, barriers, and intent to receive the influenza vaccine. We will also generate preliminary data on the acceptability, cost-effectiveness, and required capacity for facility-based influenza vaccination for informing policy decisions regarding influenza vaccination among the high-risk population in Bangladesh.</p>
              </sec>
            </sec>
            <sec id="Sec3">
              <title>Methods</title>
              <p id="Par14">This study will employ a quasi-experimental design that aligns with the STROBE guidelines. Additionally, this design will incorporate sensitivity analyses to explore the impact of uncertainty in parameter estimation precision on the outcomes of deterministic Markov decision-analytic models.</p>
              <sec id="Sec4">
                <title>Study design</title>
                <p id="Par15">We will conduct our study leveraging the ongoing HBIS platform, a network of nine tertiary-level hospitals across Bangladesh [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. The structure and operational aspects of the HBIS platform have been previously discussed [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Our study design will be quasi-experimental. To meet the vaccine acceptability objective, we will collect data on participants’ health beliefs, barriers, and vaccination intentions using the health belief model (HBM) from patients meeting criteria for high-risk populations attending two public tertiary-level hospitals. To meet the influenza vaccination cost-effectiveness objective, in one of the two hospitals, we will conduct an influenza vaccination campaign before the influenza season, where the vaccine will be offered free of cost to high-risk patients, and in the second hospital, vaccination will not be offered. Both the vaccinated and unvaccinated participants will then be followed-up once a month for one year to record any influenza-like illness, hospitalization, and death. Additional data for vaccination cost-effectiveness objectives on direct and indirect costs associated with influenza illness will be collected from ILI and SARI patients at one public and one private hospital. To meet the required capacity for a facility-based influenza vaccination objective, we will collect secondary data, including the Statistical Yearbook of Bangladesh 2020, as represented in Table <xref rid="Tab1" ref-type="table">1</xref> [<xref ref-type="bibr" rid="CR26">26</xref>–<xref ref-type="bibr" rid="CR28">28</xref>].</p>
                <p id="Par16">
                  <table-wrap id="Tab1">
                    <label>Table 1</label>
                    <caption>
                      <p>Assumptions and data sources by each target group</p>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <thead>
                        <tr>
                          <th align="left">Target Group</th>
                          <th align="left">Assumption and data sources</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left">Children 6 months to 8 years, influenza vaccine doses</td>
                          <td align="left">Two doses will be delivered, each four weeks apart [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Data of the total number of &lt; 5 years children will be adopted from the Statistical Yearbook of Bangladesh 2020 [<xref ref-type="bibr" rid="CR26">26</xref>]. Monthly the number of children &lt; 8 years visited hospitals will be collected from respected hospitals or respective District Civil Surgeon Office [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR33">33</xref>].</td>
                        </tr>
                        <tr>
                          <td align="left">Pregnant women’s influenza vaccine doses</td>
                          <td align="left">One dose to all pregnant women (any trimesters). The crude birth rate is assumed to be 21.9% (BDHS 2017-18) [<xref ref-type="bibr" rid="CR34">34</xref>]. Influenza vaccines were distributed evenly across the childbearing years 15 through 49 [<xref ref-type="bibr" rid="CR34">34</xref>]. Data on the total number of women of childbearing age (15–49 years) will be collected from the Statistical Yearbook of Bangladesh 2020 [<xref ref-type="bibr" rid="CR26">26</xref>]. Monthly pregnant women who visited hospitals will be collected from respective hospitals or respective District Civil Surgeon Office [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR33">33</xref>].</td>
                        </tr>
                        <tr>
                          <td align="left">Elderly ≥ 60 years influenza vaccine doses</td>
                          <td align="left">One dose for all persons aged 60 years and older. Population data from the Statistical Yearbook of Bangladesh 2020 [<xref ref-type="bibr" rid="CR26">26</xref>]. Monthly the total number of ≥ 60 years aged patients visited hospitals will be collected from respected hospitals or respective District Civil Surgeon Office [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR33">33</xref>].</td>
                        </tr>
                        <tr>
                          <td align="left">Adults with chronic diseases, influenza vaccine doses</td>
                          <td align="left">One dose for all persons with chronic disease. We will use the prevalence of having any chronic illness from the Bangladesh Household Income and Expenditure Survey (HIES) 2010 [<xref ref-type="bibr" rid="CR35">35</xref>]. Then, the total number of persons with any chronic illness will be estimated using data from the Statistical Yearbook of Bangladesh 2020 [<xref ref-type="bibr" rid="CR26">26</xref>]. Monthly patients with chronic diseases visited hospitals will be collected from respected hospitals or respective District Civil Surgeon Office [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR33">33</xref>].</td>
                        </tr>
                      </tbody>
                    </table>
                  </table-wrap>
                </p>
                <p id="Par17">We will conduct all the study activities through close collaboration with the Institute of Epidemiology Disease Control and Research (IEDCR) of the Ministry of Health and Family Welfare (MoH&amp;FW), the Government of Bangladesh. We will also collaborate closely with the administration of the participating hospitals, especially the hospital director, to guarantee the hospitals’ participation, support, and cooperation. We will work with the line director and directors of study hospitals to implement the vaccination. We will utilize hospital resources and leverage existing staff to vaccinate study participants. Figure <xref rid="Fig1" ref-type="fig">1</xref> illustrates the study activities and data collection flow chart.</p>
                <p id="Par18">
                  <fig id="Fig1">
                    <label>Fig. 1</label>
                    <caption>
                      <p>Flow chart showing different elements of study activity and data collection</p>
                    </caption>
                    <graphic xlink:href="12889_2024_17724_Figb_HTML" id="d32e627"/>
                  </fig>
                </p>
              </sec>
              <sec id="Sec5">
                <title>Study setting</title>
                <p id="Par19">We selected study hospitals considering several factors. Firstly, we will use the hospital-based influenza surveillance (HBIS) platform to conduct this study. We have chosen Rajshahi Medical College Hospital and Khulna Medical College Hospital for our study activities on high-risk groups’ vaccine acceptability and cost-effectiveness. We will enroll Severe acute respiratory illness (SARI) and influenza like illness (ILI) patients identified from the HBIS platform to meet our study objectives. We will also collect influenza virus test results from the HBIS platform and data on influenza illness episodes’ costs from the influenza-positive SARI and ILI patients. This approach will save influenza virus testing costs not allocated in the current study budget. Secondly, to assess the outcome of influenza vaccination, we plan to enroll patients from public tertiary-level hospitals (one treatment/vaccinated and the other control hospital) to minimize baseline differences between the treatment/vaccinated and control arm. Thirdly, we have chosen Ragib-Rabeya Medical College &amp; Hospital to represent public and private healthcare facility cost differences while estimating the costs of influenza illness. A brief description of the study sites’ bed occupancy rate and average monthly admission are represented in Table <xref rid="Tab2" ref-type="table">2</xref> [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>].</p>
                <p id="Par20">
                  <table-wrap id="Tab2">
                    <label>Table 2</label>
                    <caption>
                      <p>Demographic characteristics of the study hospitals</p>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <thead>
                        <tr>
                          <th align="left">Study sites</th>
                          <th align="left">Bed occupancy rate (%)</th>
                          <th align="left">Total no OPD visits</th>
                          <th align="left">Total number of PNC visits</th>
                          <th align="left">Total number of admission</th>
                          <th align="left">Middle wealth quantile</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left">Rajshahi Medical College Hospital</td>
                          <td align="left">198.05</td>
                          <td align="left">114,818</td>
                          <td align="left">2,405</td>
                          <td align="left">22,022</td>
                          <td align="left">24.1%</td>
                        </tr>
                        <tr>
                          <td align="left">Khulna Medical College Hospital</td>
                          <td align="left">275.00</td>
                          <td align="left">35,311</td>
                          <td align="left">991</td>
                          <td align="left">8,859</td>
                          <td align="left">24.8%</td>
                        </tr>
                        <tr>
                          <td align="left">Jalalabad Ragib-Rabeya Medical College &amp; Hospital</td>
                          <td align="left">NA</td>
                          <td align="left">NA</td>
                          <td align="left">NA</td>
                          <td align="left">NA</td>
                          <td align="left">15.8%</td>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot>
                      <p>Source: Local health bulletin October 2022</p>
                      <p>OPD = outpatients care department; PNC = post-natal visit</p>
                      <p>Note: a bed occupancy rate greater than 100% indicates that these hospitals receive and care for more patients than their capacity</p>
                    </table-wrap-foot>
                  </table-wrap>
                </p>
                <p id="Par21">Study sites for influenza vaccine acceptability, health beliefs, barriers:</p>
                <p id="Par22">We will conduct a health belief model (HBM) survey in two conveniently selected hospitals:</p>
                <p id="Par23">
                  <list list-type="order">
                    <list-item>
                      <p id="Par24">Rajshahi Medical College Hospital, Rajshahi.</p>
                    </list-item>
                    <list-item>
                      <p id="Par25">Khulna Medical College Hospital, Khulna.</p>
                    </list-item>
                  </list>
                </p>
                <p id="Par26">Study sites for influenza vaccination cost-effectiveness objective:</p>
                <p id="Par27">For this specific objective, we will collect data on the health outcome of vaccination and the cost associated with influenza illness. Data on health outcomes will be collected from two public tertiary-level hospitals. The cost associated with influenza illness data will be collected from one public and one private hospital. Figure <xref rid="Fig2" ref-type="fig">2</xref> represents the study sites.</p>
                <p id="Par28">
                  <fig id="Fig2">
                    <label>Fig. 2</label>
                    <caption>
                      <p>Location of the study hospitals; red ellipse represents Rajshahi Medical College Hospital, Rajshahi; red rectangle represents Jalalabad Ragib-Rabeya Medical College &amp; Hospital; red triangle represents Khulna Medical College Hospital</p>
                    </caption>
                    <graphic xlink:href="12889_2024_17724_Figa_HTML" id="d32e748"/>
                  </fig>
                </p>
                <p id="Par29">Health outcomes of vaccination:</p>
                <p id="Par30">
                  <list list-type="order">
                    <list-item>
                      <p id="Par31">Rajshahi Medical College Hospital, Rajshahi.</p>
                    </list-item>
                    <list-item>
                      <p id="Par32">Khulna Medical College Hospital, Khulna.</p>
                    </list-item>
                  </list>
                </p>
                <p id="Par33">Cost associated with influenza illness:</p>
                <p id="Par34">
                  <list list-type="order">
                    <list-item>
                      <p id="Par35">Rajshahi Medical College Hospital, Rajshahi.</p>
                    </list-item>
                    <list-item>
                      <p id="Par36">Jalalabad Ragib-Rabeya Medical College &amp; Hospital, Sylhet.</p>
                    </list-item>
                  </list>
                </p>
                <p id="Par37">Study sites for required capacity for a facility-based influenza vaccination objective:</p>
                <p id="Par38">We will utilize secondary data to estimate the required capacity for seasonal influenza vaccination at three hospital catchment areas, as illustrated in Table <xref rid="Tab1" ref-type="table">1</xref>.</p>
              </sec>
              <sec id="Sec6">
                <title>Study population and participant recruitment</title>
                <p id="Par39">The study population will consist of persons belonging to the four high-risk groups as defined by the World Health Organization (WHO), except for healthcare workers: children six months to eight years, pregnant women, elderly ≥ 60 years, and adults with chronic diseases [<xref ref-type="bibr" rid="CR7">7</xref>]. We have excluded healthcare workers from our targeted study population to prevent duplication with our prior research efforts [<xref ref-type="bibr" rid="CR19">19</xref>]. We will enroll study participants who meet specific inclusion and exclusion criteria. Table <xref rid="Tab3" ref-type="table">3</xref> depicts the criteria utilized to determine the inclusion and exclusion of participants in our study.</p>
                <p id="Par40">
                  <table-wrap id="Tab3">
                    <label>Table 3</label>
                    <caption>
                      <p>List inclusion and exclusion criteria</p>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <thead>
                        <tr>
                          <th align="left">Inclusion criteria</th>
                          <th align="left">Exclusion criteria</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left">Participants will be visiting study hospitals (outpatients and inpatients only. Not emergency departments) for routine care during the study period.</td>
                          <td align="left">Participants with severe, life-threatening allergies to any ingredient in a flu vaccine (other than egg proteins)</td>
                        </tr>
                        <tr>
                          <td align="left">Participants who will be children six months to eight years, or aged more than 60 years, or pregnant women (any trimester), or have any chronic disease such as chronic respiratory disease (requiring regular medication), diabetes, chronic renal disease, any cancer, excluding basal and squamous skin cancers, immune suppression or immune deficiency, chronic liver disease, chronic hematological disorder, chronic kidney disease, chronic neurological impairment/disease, serious mental health condition, organ or bone marrow recipient, history of any prior surgery, percutaneous coronary intervention, high blood cholesterol, family history of cardiovascular disease, other pre-existing conditions.</td>
                          <td align="left">Participants having a history of severe allergic reactions (e.g., anaphylaxis) after a previous dose of influenza vaccine or to a vaccine component.</td>
                        </tr>
                        <tr>
                          <td align="left">Participants /parents/caregivers who will be willing to sign the informed consent form</td>
                          <td align="left">Participants having a history of Guillain-Barre syndrome less than six weeks after a previous dose of influenza vaccine.</td>
                        </tr>
                        <tr>
                          <td align="left">Participants/parents/caregivers who will have an operational mobile phone number and are responsible for sharing updated phone numbers in case of plans to change for the next year</td>
                          <td align="left">Participants having a history of moderate or severe acute illness with or without fever. The vaccine should be given after the acute condition has improved.</td>
                        </tr>
                        <tr>
                          <td align="left">Participants/parents/caregivers who will have fixed addresses with no plan to leave the address for the next one year</td>
                          <td align="left"/>
                        </tr>
                        <tr>
                          <td align="left">Participants/parents/caregivers will be aware of the follow-up schedule and understand the study expectations during the follow-up.</td>
                          <td align="left"/>
                        </tr>
                      </tbody>
                    </table>
                  </table-wrap>
                </p>
              </sec>
              <sec id="Sec7">
                <title>Variables</title>
                <p id="Par41">We thoroughly reviewed the literature on different outcome variables and explanatory factors in our research [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR36">36</xref>–<xref ref-type="bibr" rid="CR44">44</xref>]. Regarding our first objective, which centered on vaccine acceptability, our primary outcome of interest wil be the high-risk groups’ intention to receive the influenza vaccination. This will assist us in assessing the propensity of high-risk groups’ willingness to receive influenza vaccine. Our second objective focuses on vaccination effectiveness, precisely measuring vaccine efficacy against influenza in high-risk group groups. This metric will enable us to assess the efficacy of the vaccination in protecting high-risk group groups. In addition, we will thoroughly examine the cost components related to influenza, focusing on the overall costs of influenza-related illnesses in high-risk groups as our second objective’s variables. To understand the complex factors that affect vaccine acceptance and effectiveness, we will examine various explanatory variables, including age, gender, occupation, location, marital status, and income, among others.</p>
              </sec>
              <sec id="Sec8">
                <title>Data sources and measurement</title>
                <sec id="Sec9">
                  <title>Data collection to assess health beliefs, barriers, and intention to receive an influenza vaccine</title>
                  <p id="Par42">We will collect data on acceptability, health beliefs, obstacles, and current intentions to receive the vaccine from enrolled participants (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). We will capture these data using the health belief model (HBM). The questionnaire has been developed using an existing literature review [<xref ref-type="bibr" rid="CR36">36</xref>–<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. We will include items to assess five theoretical constructs of HBM based on reviewing relevant literature, including high-risk individual’s perceived susceptibility to disease, perceived severity of influenza, perceived benefits of the vaccine, perceived barriers to the vaccine, cues to action, and self-efficacy [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. We will conduct face-to-face interviews for the data collection.</p>
                </sec>
              </sec>
              <sec id="Sec10">
                <title>Data collection to determine vaccination cost-effectiveness</title>
                <sec id="Sec11">
                  <title>Vaccination campaign</title>
                  <p id="Par43">To record health outcomes after influenza vaccination, in one of the two public tertiary-level study hospitals, we will conduct an influenza vaccination campaign before the influenza season, where the vaccine will be offered free of cost to high-risk patients, and in the second hospital, vaccination will not be offered. We will work with the hospital administration to set up a vaccination booth on the hospital premises. Vaccines will be made available at the vaccination booths. Posters and leaflets containing information on influenza vaccination will be displayed at the vaccination booths and key hospital locations with information on the vaccination. Inpatients and outpatients of all departments will be informed about the ongoing immunization campaign. Eligible patients will be offered to take the vaccine during the vaccination campaign. Benefits, significance, adverse effects, and how to manage them will be explained to the patients. Nurses/ Health Assistants (HA) will provide influenza vaccination throughout the campaigns. At 8 AM, the vaccination booth will open and close at 2 PM, six days a week throughout the campaign period. A vaccination card will be issued to the participants. All high-risk groups will get one dose of seasonal influenza vaccination (Quadrivalent), except children aged six months to 8 years, who will receive two doses four weeks apart [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. All vaccines will be the southern hemisphere vaccine as recommended by the WHO for Bangladesh. Regarding children, we will make phone follow-ups with the guardians of the children receiving the first dose to remind them about the second dose schedule, and it will be recorded in the vaccine card if the second dose is received. In order to ensure the availability and quality control of vaccines throughout the three-month campaign period, the research team at icddr,b will closely monitor the campaign. All vaccinated participants will receive notification regarding potential adverse events following immunization (AEFI) during the vaccination process. To document any untoward occurrences after Adverse Events Following Immunization (AEFI), we will adhere to the pre-existing surveillance mechanism implemented by the World Health Organization (WHO) and the Ministry of Health and Family Welfare (MoHFW) of the government of Bangladesh. During the vaccination campaign briefing session in each study hospital, participants will be informed about the process of reporting any Adverse Events Following Immunization (AEFI) within the hospital’s established surveillance system. Additionally, participants will be provided with the mobile number, as stated in the consent form, to report any such issues. Furthermore, during the vaccination campaign implementation, a representative from icddr,b will be assigned to each study hospital to oversee and monitor any adverse events following immunization (AEFI) in conjunction with the hospital’s existing surveillance system. If an Adverse Event Following Immunization (AEFI) case is identified, the personnel affiliated with icddr,b will promptly notify the Hospital Surveillance Officer (HSO), provide support to the HSO in completing the AEFI report form, and subsequently transmit it to the Expanded Programme on Immunization (EPI) headquarters via the Chief Health Officer.</p>
                  <p id="Par44">In the second hospital, we will enroll participants meeting the high-risk group individual criteria. However, no vaccination campaign will be conducted. We will name this group as an unvaccinated cohort.</p>
                </sec>
              </sec>
              <sec id="Sec12">
                <title>Follow-up of vaccinated and unvaccinated participants</title>
                <p id="Par45">icddr,b field staff will follow up with vaccinated and unvaccinated study participants bi-weekly through mobile phone for the entire influenza season. During the follow-up, data will be recorded on health outcomes, including respiratory symptoms, influenza-like illness, hospitalization, and death. To minimize loss to follow-up, icddr,b field team will contact the cohort member at their convenience. icddr,b field team will use the alternative number collected during enrolment where they cannot reach their regular mobile phone number. At the end of one follow-up interview, the interviewee will be consulted about the convenient time of their upcoming follow-up date. After taking these approaches, if it is impossible to reach a cohort member for three follow-up schedules, he/she will be declared lost to follow-up case. For the loss to follow-up case, icddr,b field team will place notes on their data identification number. The study flow chart is shown in Fig. <xref rid="Fig2" ref-type="fig">2</xref>.</p>
              </sec>
              <sec id="Sec13">
                <title>The cost associated with influenza illness</title>
                <p id="Par46">For collecting data on costs associated with influenza illness, we will enroll high-risk individuals visiting study hospitals who will meet the SARI and ILI case definitions:</p>
                <p id="Par47">Severe acute respiratory illness (SARI): In the case of patients across all ages, the presence of a history of or a recorded temperature equal to or exceeding 38.0 °C and cough began during the last ten days and required hospitalization [<xref ref-type="bibr" rid="CR47">47</xref>].</p>
                <p id="Par48">Influenza-like illness (ILI): Measured fever above ≥ 38.0 °C with cough having an onset within the last ten days [<xref ref-type="bibr" rid="CR47">47</xref>].</p>
                <p id="Par49">We will collect data on the enrolled participants’ direct and indirect medical costs associated with influenza illness episodes. Cost breakdowns for influenza illness episodes are provided below.</p>
              </sec>
              <sec id="Sec14">
                <title>Direct medical and non-medical costs for influenza illness episodes</title>
                <p id="Par50">Direct costs will consist of health care provider fees, hospital registration fees, bed rental, prescriptions, laboratory testing, transportation, and mobile phone calls. We will also record informal payments made during hospital visits. All medications, laboratory tests, registration, and room rental costs will also be included. We will also collect payment if patients visit a pharmacy or other clinics prior to hospitalization. The non-medical expenses for patients or caregivers include food, lodging, and transportation. Our field staff will collect data directly from patients and their families. Members of the participant’s family or the participants themselves will be able to determine the drugs and tests they received at no cost due to hospital subsidies and those for which they incurred personal expenses (out-of-pocket).</p>
              </sec>
              <sec id="Sec15">
                <title>Productivity loss or indirect cost</title>
                <p id="Par51">We will also collect data on participants’ or caregivers’, or family members’ lost productivity and indirect costs incurred during illness. We will record the number of workdays missed by participants’ family members, participants themselves, and caregivers due to sickness or family caregiving. We will exclude weekends and national holidays from our calculation. Every day missed due to illness or the need to care for sick family members will be considered a forfeited workday for hourly-wage workers and housewives. We will not consider the days missed due to decreased activity, such as a partial work day, absences from school, or fatalities caused by influenza. The number of productive days lost due to influenza-related fatalities will be estimated based on the baseline mortality rate. This will be multiplied by the median daily wage in Bangladesh, followed by an adjustment based on the prevailing unemployment rate in the country.</p>
              </sec>
              <sec id="Sec16">
                <title>Costs of durable equipment and other fixed costs</title>
                <p id="Par52">We will collect the primary data on the costs of the supplies and materials consumed (not purchased and stored) at the hospitals involved in diagnosing and treating influenza illness by department, ward, and service, for example, per unit cost and required units for blood drawn, x-ray, blood culture test, C-reactive protein, widal test, complete blood count, etc. We will also collect data related to health facility operating hours (working hours by ward and department), the ticket prices of different departments’ inpatient or outpatient units, and bed rent.</p>
              </sec>
              <sec id="Sec17">
                <title>Collating secondary data for estimating cost-effectiveness of vaccination</title>
                <sec id="Sec18">
                  <title>Disability-adjusted life year (DALY)</title>
                  <p id="Par53">We will collect secondary data on disability-adjusted life years (DALY) from the WHO global health estimation [<xref ref-type="bibr" rid="CR48">48</xref>]. We will utilize age, and symptoms-specific DALY estimates to determine the DALY associated with influenza-related health outcomes. Though QALY is widely used for hospital patients, due to the unavailability of publicly available QALY data related to influenza or influenza-like illnesses for LMICs, we have decided to use the WHO’s publicly available DALY estimates for our study. We will utilize the WHO-recommended information spreadsheet. The spreadsheet contains estimates for disability-adjusted life year (DALY), categorized by WHO region, cause, age, and sex. The term “regional classification” pertains to the World Health Organization’s regional groupings as of 2019, which aligns with the most up-to-date reference year for this Global Health Estimates revision. The compilation of these statistics was carried out by the Department of Data and Analytics at the World Health Organization (WHO) in partnership with various technical programs within the WHO. The cause-specific estimates may exhibit significant ranges of uncertainty depending on the data sources that are accessible [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. The WHO Department of Data and Analytics prepared these statistics in collaboration with WHO technical programs [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. The cause-specific estimates may exhibit significant ranges of uncertainty depending on the data sources that are accessible. Due to alterations in data and some methods, these estimates are not comparable to previously released WHO estimates. Similar literature has been identified about facility-based vaccination, wherein the DALY metric was employed to assess the cost-effectiveness of such programme [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>].</p>
                </sec>
                <sec id="Sec19">
                  <title>Data sources for estimating influenza-associated disease burden</title>
                  <p id="Par54">To estimate the key parameters of influenza-associated disease burden, such as the number of outpatient visits, hospitalization, and deaths, we will collect data from secondary sources [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR54">54</xref>–<xref ref-type="bibr" rid="CR58">58</xref>]: Table <xref rid="Tab1" ref-type="table">1</xref> represents the assumption and secondary data sources by each target risk group.</p>
                </sec>
                <sec id="Sec20">
                  <title>Vaccine coverage</title>
                  <p id="Par55">We will use secondary data for the input parameters relating to seasonal influenza vaccination coverage in Bangladesh [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR59">59</xref>–<xref ref-type="bibr" rid="CR61">61</xref>]. We will use our proposed study data on the number of targeted high-risk group individuals getting influenza vaccination during the immunization campaign to estimate vaccine coverage [<xref ref-type="bibr" rid="CR62">62</xref>]. We will extract information on hospitals’ catchment areas’ population size from the Statistical Yearbook of Bangladesh 2020 [<xref ref-type="bibr" rid="CR26">26</xref>].</p>
                </sec>
                <sec id="Sec21">
                  <title>Vaccine adverse event costs</title>
                  <p id="Par56">Vaccine adverse event costs will be estimated for each targeted risk group. Using primary and secondary data, we will estimate the costs of influenza vaccination adverse events. We will use secondary data to estimate influenza vaccination rates and adverse events, whereas primary data will be used to determine the cost [<xref ref-type="bibr" rid="CR34">34</xref>]. We will assume that patients who have a minor adverse event will seek medical care at an outpatient facility where they will receive consultation from a qualified physician. On the other hand, all patients who experience a severe adverse event will need hospitalization. The unit cost for minor adverse events will be determined by the price charged by the outpatient care department and the fee charged by the physician. Fees for outpatient care departments and healthcare professionals will be derived from primary data. Similarly, the estimation of the cost associated with a severe adverse event involves the calculation of inpatient care costs, which encompass both general ward facility fees and specialist fees. This estimation is derived by multiplying these costs by the length of the patient’s hospital stay. The average duration of hospital stay for influenza-associated illnesses will be collected from secondary data, and inpatient care daily costs will be collected from primary data [<xref ref-type="bibr" rid="CR63">63</xref>].</p>
                </sec>
                <sec id="Sec22">
                  <title>Influenza vaccination programme cost</title>
                  <p id="Par57">The financial and economic costs associated with the vaccination programme will be assessed through the utilization of the World Health Organization’s Seasonal Influenza Immunization Costing Tool (SIICT) [<xref ref-type="bibr" rid="CR64">64</xref>]. The WHO SIICT was updated in 2020 and was newly named “The WHO Flutool Plus” [<xref ref-type="bibr" rid="CR64">64</xref>]. The newly developed WHO Flutool Plus enables the estimation of costs associated with various vaccination activities, including microplanning, procurement, distribution, training, social mobilization, service delivery, supervision, and the acquisition of supplemental cold chain equipment [<xref ref-type="bibr" rid="CR64">64</xref>]. We will customize the Flutool Plus as required to estimate the cost of our facility-based vaccination programme. During the vaccination campaign, icddr,b research personnel will keep track of all cost components of the influenza vaccine campaign. The cost components of the vaccination campaign at the facility level that will be recorded are shown in Table <xref rid="Tab4" ref-type="table">4</xref>.</p>
                  <p id="Par58">
                    <table-wrap id="Tab4">
                      <label>Table 4</label>
                      <caption>
                        <p>Cost components of the facility-based piloted influenza vaccination campaign</p>
                      </caption>
                      <table frame="hsides" rules="groups">
                        <thead>
                          <tr>
                            <th align="left">Dimension</th>
                            <th align="left">Components of costs</th>
                          </tr>
                        </thead>
                        <tbody>
                          <tr>
                            <td align="left" colspan="2">
                              <bold>Start-up cost</bold>
                            </td>
                          </tr>
                          <tr>
                            <td align="left">Micro-planning</td>
                            <td align="left">
                              <p>• Personnel time spent in meetings</p>
                              <p>• Per diems and travel allowances</p>
                              <p>• Venue rental</p>
                              <p>• Transport</p>
                            </td>
                          </tr>
                          <tr>
                            <td align="left">Training</td>
                            <td align="left">
                              <p>• Value of personnel time spent on training</p>
                              <p>• Development of training materials</p>
                              <p>• Per diems and travel allowances</p>
                              <p>• Venue rental</p>
                              <p>• Transport</p>
                              <p>• Training materials</p>
                              <p>• Stationery</p>
                            </td>
                          </tr>
                          <tr>
                            <td align="left">Social mobilization/IEC</td>
                            <td align="left">
                              <p>• Value of personnel and volunteer time spent on material development and other activities</p>
                              <p>• Facilitator time in meetings</p>
                              <p>• Per diems and travel allowances</p>
                              <p>• Stationery</p>
                              <p>• Printing of posters and leaflets</p>
                              <p>• Production of TV and/or radio spots</p>
                            </td>
                          </tr>
                          <tr>
                            <td align="left" colspan="2">
                              <bold>Recurrent or operational costs</bold>
                            </td>
                          </tr>
                          <tr>
                            <td align="left">Procurement of vaccines and injection supplies</td>
                            <td align="left">
                              <p>• Cost of vaccines and injection supplies, regardless of the source of financing</p>
                              <p>• Cost of freight, clearance, insurance, and taxes</p>
                            </td>
                          </tr>
                          <tr>
                            <td align="left">Service delivery</td>
                            <td align="left">
                              <p>• Value of personnel time spent on vaccination</p>
                              <p>• Transport fuel</p>
                              <p>• Personnel per diems to travel to vaccination sites</p>
                              <p>• Supplies– e.g. cotton</p>
                            </td>
                          </tr>
                          <tr>
                            <td align="left">Monitoring and evaluation</td>
                            <td align="left">
                              <p>• Tally sheets or registers</p>
                              <p>• Pens and pencils</p>
                              <p>• Vaccination cards</p>
                              <p>• Materials for vaccine booths</p>
                            </td>
                          </tr>
                          <tr>
                            <td align="left">Supervision</td>
                            <td align="left">
                              <p>• Value of personnel time spent on supervision</p>
                              <p>• Travel allowances</p>
                              <p>• Transport fuel and maintenance</p>
                              <p>• Stationery</p>
                            </td>
                          </tr>
                          <tr>
                            <td align="left">Waste management</td>
                            <td align="left">
                              <p>• Purchase of incinerators (annualized/discounted)</p>
                              <p>• Fuel</p>
                              <p>• Transport</p>
                            </td>
                          </tr>
                          <tr>
                            <td align="left" colspan="2">
                              <bold>Capital costs</bold>
                            </td>
                          </tr>
                          <tr>
                            <td align="left">Cold chain equipment</td>
                            <td align="left">Cold chain equipment (annualized and discounted)</td>
                          </tr>
                        </tbody>
                      </table>
                    </table-wrap>
                  </p>
                </sec>
              </sec>
              <sec id="Sec23">
                <title>Data sources for determining the required capacity of facility-based influenza vaccination</title>
                <p id="Par59">We will estimate the required capacity of the seasonal influenza vaccination programme based on the cold chain capacity requirements of the hospitals. We will also collect secondary data to calculate requirements at each hospital.</p>
                <p id="Par60">Secondary data will be collected about the population size of the targeted risk group in the hospital’s catchment area, the number of doses required for vaccinating each high-risk individual, the number of doses per vial, packed volume, doses syringes, and safety box [<xref ref-type="bibr" rid="CR26">26</xref>–<xref ref-type="bibr" rid="CR30">30</xref>]. Table <xref rid="Tab1" ref-type="table">1</xref> represents the assumptions on the population size of the targeted risk group in the catchment area.</p>
              </sec>
            </sec>
            <sec id="Sec24">
              <title>Study size</title>
              <sec id="Sec25">
                <title>Sample size and sampling</title>
                <sec id="Sec26">
                  <title>The sample size for the vaccine acceptability objective</title>
                  <p id="Par61">Our study design will be quasi-experimental. Our primary outcome for vaccine acceptability is the intention to receive the influenza vaccine. Based on studies utilizing the high-risk group-specific health belief model conducted in neighboring countries, it has been found that 91% of elderly people, 88% of adults with chronic illness, 76.3% of pregnant women, and 62.4% of parents with six to three-year-olds expressed their intention to get the influenza vaccine [<xref ref-type="bibr" rid="CR38">38</xref>–<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. We expect a similar positive intention to receive the influenza vaccine, ranging from 62 to 91% for our target study population. In this study, we employed a significance level of 5%, a power of 80%, a design effect of 1.2, and account for a non-response rate of 10% to determine the required sample size [<xref ref-type="bibr" rid="CR65">65</xref>–<xref ref-type="bibr" rid="CR67">67</xref>]. We will utilize a validated health belief model tool. To avoid selection bias, we will use random assignment to the study based on predefined inclusion and exclusion criteria. We will also provide training to study staff about random enrolment of the study participants based on inclusion and exclusion criteria. Table <xref rid="Tab5" ref-type="table">5</xref> represents the estimated sample size by the high-risk group for the vaccine acceptability objective.</p>
                  <p id="Par62">
                    <table-wrap id="Tab5">
                      <label>Table 5</label>
                      <caption>
                        <p>Estimated sample size for investigating the vaccine acceptability/ intention to receive, health outcome due to vaccination, and cost-effectiveness of implementing a facility-based influenza vaccination</p>
                      </caption>
                      <table frame="hsides" rules="groups">
                        <thead>
                          <tr>
                            <th align="left">High-risk group</th>
                            <th align="left">The sample size for the vaccine acceptability survey</th>
                            <th align="left">The sample size for vaccine effectiveness</th>
                            <th align="left">The sample size for the cost-components survey</th>
                          </tr>
                        </thead>
                        <tbody>
                          <tr>
                            <td align="left">Children 6 months to 8 years</td>
                            <td align="left">659</td>
                            <td align="left">465</td>
                            <td align="left">60</td>
                          </tr>
                          <tr>
                            <td align="left">Pregnant women</td>
                            <td align="left">495</td>
                            <td align="left">756</td>
                            <td align="left">39</td>
                          </tr>
                          <tr>
                            <td align="left">Elderly ≥ 60 years</td>
                            <td align="left">330</td>
                            <td align="left">736</td>
                            <td align="left">56</td>
                          </tr>
                          <tr>
                            <td align="left">Adults with chronic diseases</td>
                            <td align="left">425</td>
                            <td align="left">610</td>
                            <td align="left">31</td>
                          </tr>
                        </tbody>
                      </table>
                    </table-wrap>
                  </p>
                </sec>
                <sec id="Sec27">
                  <title>The sample size for the vaccine effectiveness objective</title>
                  <p id="Par63">Our primary outcome for health outcome for vaccination is vaccine efficacy against influenza among high-risk group populations. Studies from neighboring countries found that ILI symptoms were 15.30% of children, 31.23% of adults with chronic illness, 10.97% of pregnant women, and 20% of the elderly [<xref ref-type="bibr" rid="CR68">68</xref>–<xref ref-type="bibr" rid="CR70">70</xref>]. A systematic review of seasonal influenza vaccine policy, use, and effectiveness also revealed that pooled vaccine effectiveness for high-risk groups in the tropics and subtropics ranged from 48 to 88% (10). We expect a similar vaccine efficacy between 50 and 81% for our study’s targeted high-risk group population. A 5% significance level, 80% power, design effect 1.2, and 10% non-response were used to calculate the required sample size to estimate vaccine effectiveness [<xref ref-type="bibr" rid="CR65">65</xref>–<xref ref-type="bibr" rid="CR67">67</xref>]. Table <xref rid="Tab5" ref-type="table">5</xref> represents the high-risk group’s estimated sample size for vaccine effectiveness.</p>
                </sec>
                <sec id="Sec28">
                  <title>The sample size for the cost-components survey</title>
                  <p id="Par64">Our primary outcome for costs-components is the total influenza-associated illness costs among high-risk group populations. A study conducted in Bangladesh examined the economic assessment of diseases associated with influenza [<xref ref-type="bibr" rid="CR3">3</xref>]. The findings indicated that the overall direct costs related to influenza-induced illness were estimated at USD 70 (7,614 Taka) for children under the age of five [<xref ref-type="bibr" rid="CR3">3</xref>]. Pregnant women incurred costs of USD 191 (20,808 Taka), while the elderly faced expenses of USD 126 (13,761 Taka) [<xref ref-type="bibr" rid="CR3">3</xref>]. Adults with chronic diseases had direct costs amounting to USD 75 (8,222 Taka) [<xref ref-type="bibr" rid="CR3">3</xref>]. Our study anticipates a comparable aggregate direct cost of influenza-related illness ranging from USD 70 (7,614 Taka) to USD 191 (20,808 Taka) for the specific population of high-risk individuals we targeted. Other than that, our study employed a significance level of 5%, a power of 80%, a design effect of 1.2, and accounts for a non-response rate of 10% to determine the appropriate sample size [<xref ref-type="bibr" rid="CR65">65</xref>–<xref ref-type="bibr" rid="CR67">67</xref>]. Table <xref rid="Tab5" ref-type="table">5</xref> represents the high-risk group’s estimated sample size for vaccine effectiveness. For both of our objectives, we will screen and enroll study participants from both inpatient and outpatient across all clinical departments of the study hospitals, who will be seeking routine care and treatment at the study hospitals.</p>
                </sec>
                <sec id="Sec29">
                  <title>Quantitative variables</title>
                  <p id="Par65">We will conduct a thorough literature review to help us choose the quantitative variables for our study, drawing upon a range of sources [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR36">36</xref>–<xref ref-type="bibr" rid="CR44">44</xref>]. The variables will be categorized into three broad categories. Firstly, we will encompass sociodemographic variables, which consist of a wide range of sociodemographic data related to the specific high-risk group being studied. Secondly, in the medical history section, we included variables regarding the medical history of individuals at high risk and any common signs and symptoms they experienced in the previous 30 days. The third category includes direct and indirect cost components related to using medical resources for SARI and ILI. These variables include expenses that occur before, during, and after receiving treatment for SARI and ILI. This provides a thorough understanding of the economic factors associated with these conditions.</p>
                </sec>
              </sec>
            </sec>
            <sec id="Sec30">
              <title>Statistical methods</title>
              <p id="Par66">We will summarize all the data using various descriptive statistics tools, such as frequency, percentage, mean, median, standard deviation (SD), and interquartile range (IQR, calculated as the difference between the 25th percentile and the 75th percentile).</p>
              <sec id="Sec31">
                <title>Objective specific data analysis plan is as follows</title>
                <sec id="Sec32">
                  <title>Data analysis on the propensity to vaccine using results from the vaccine acceptability survey</title>
                  <p id="Par67">In each of the five HBM constructs, we will use factor analysis using the principal axis factor technique and varimax rotation to find latent variables and minimize the number of independent variables. The Kaiser-Meyer-Olkin test will be used to determine sample adequacy. The parameters that suggest an acceptable fit on the factor analysis will be the goodness of fit index (GFI) and root mean square error of approximation (RMSEA) [<xref ref-type="bibr" rid="CR71">71</xref>]. We will also use Cronbach’s alpha to assess the internal consistency of survey items [<xref ref-type="bibr" rid="CR45">45</xref>]. We will use the regression models with robust error estimation to predict and understand the association between influenza vaccination status and all five HBM constructs.</p>
                </sec>
              </sec>
              <sec id="Sec33">
                <title>Data analysis for cost-effectiveness analysis</title>
                <sec id="Sec3113">
                  <title>Vaccine efficacy estimation</title>
                  <p id="Par68">We will utilize Poisson regression to calculate the rate ratios (RRs) of participants who will receive influenza vaccination compared to those who will not. In the final model, we will include all the variables that will incorporate all variables that exhibit a confounding effect or demonstrate statistical significance at a significance level of 5%. The investigation of additional potential effect modifiers will be conducted by incorporating interaction terms. We will calculate vaccine effectiveness with 95% CI for each risk group ( (1 - RR) * 100) [<xref ref-type="bibr" rid="CR72">72</xref>].</p>
                </sec>
                <sec id="Sec34">
                  <title>Cost-effectiveness estimation</title>
                  <p id="Par69">To estimate the cost-effectiveness of our pilot influenza vaccination porgramme targeted for the high-risk group, we will use the built-in formulas of the CETSIV tool. The CETSIV is a Microsoft Excel-based tool designed to analyze the cost-effectiveness of influenza vaccination using a decision tree model [<xref ref-type="bibr" rid="CR43">43</xref>]. It features built-in formulas for deterministic Markov decision-analytic models to evaluate the incremental costs and DALY of the vaccination compared to a controlled scenario [<xref ref-type="bibr" rid="CR43">43</xref>]. Besides, we will recheck the outputs by developing a deterministic Markov decision-analytic model to simulate outcomes under alternative assumptions of input parameters. Individual DALYs will be calculated for each risk group’s individual using the WHO global health estimates for DALYs [<xref ref-type="bibr" rid="CR49">49</xref>]. Incremental cost-effectiveness ratios (ICERs) will be calculated as the ratio of incremental cost over incremental DALYs. We will conduct a probabilistic sensitivity analysis (PSA) to see how parameter estimation precision uncertainty affects the model’s outcome. Since we will develop a cohort-based Markov model, each model had different years of estimation depending on the age at which each cohort enters the mode. Hence, such calculated ICERs will be measured using different future time frames. In order to ensure consistency of ICERs across all cohorts, the discount will be applied to ICERs using the number of years remaining life years. We will assume a life expectancy of 75 and a discount rate of 5%. Identified key parameters will change simultaneously over predetermined probability distribution. The Markov model will be run 1,000 times for each risk group, assuming variations in key parameters using pre-defined probabilities to allow for uncertainty in parameters. If ICER is below less than three times the gross domestic product (GDP) per capita, we will consider the vaccination as cost-effective, as per the WHO standard [<xref ref-type="bibr" rid="CR73">73</xref>–<xref ref-type="bibr" rid="CR76">76</xref>]. Also, we will estimate rates of influenza cases averted /outpatient visits averted/hospitalization averted/ deaths averted, or influenza treatment cost or productivity loss averted by influenza vaccination in each risk group using the method described by Meredith et al. 2019 [<xref ref-type="bibr" rid="CR77">77</xref>].</p>
                </sec>
              </sec>
              <sec id="Sec35">
                <title>Data analysis to calculate the required capacity of facility-based influenza vaccination</title>
                <p id="Par70">We will estimate annual influenza vaccine dose and safe-injection equipment requirements for the target hospitals, adopting the WHO guidelines to calculate vaccine volumes and cold chain capacity [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR79">79</xref>]. We will also estimate the required storage volume, shortage volume for the vaccine, and safe injection [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR79">79</xref>]. We will compare the anticipated vaccine volumes to the vaccine cold storage capacity estimates to assess the hospital’s operational feasibility.</p>
              </sec>
              <sec id="Sec36">
                <title>Vaccination cost estimation</title>
                <p id="Par71">We will be using the Flutool Plus add-on for Excel. Flutool Plus calculates each cost type’s financial and economic costs and displays the results. Besides Flutool Plus calculation, we will also calculate each cost type’s financial and economic costs for cross-checking purposes. To do so, we will multiply the data input quantities by the financial and economic unit costs to get the incremental financial and economic costs. However, the Flutool Plus tool’s default adjustment parameters, including the dollar exchange rate and inflation rate, were developed in 2021. We assume a discount rate of 5%. Bangladesh Bank’s dollars exchange rate of Tk.105 to Tk.110 will be used to represent the findings at all estimates [<xref ref-type="bibr" rid="CR80">80</xref>]. According to the Bangladesh Bank, the inflation rate will also be adjusted with all of our estimates [<xref ref-type="bibr" rid="CR81">81</xref>]. We will follow the process for four high-risk groups.</p>
              </sec>
              <sec id="Sec37">
                <title>Data safety monitoring plan (DSMP)</title>
                <p id="Par72">The data collected from the participants will be treated with confidentiality, utilizing a unique identification code. The privacy of participants’ data will be ensured, and all data gathered during the research will be maintained in strict confidentiality, with no sharing of information with any other parties. Additionally, strict controls will be implemented to regulate access to the data forms, and strict adherence to preserving data confidentiality will be upheld. The survey responses provided by participants will be treated with strict confidentiality, ensuring that no personal identifying information, including participant names, will be shared.</p>
              </sec>
            </sec>
            <sec id="Sec38" sec-type="discussion">
              <title>Discussion</title>
              <p id="Par73">While research indicates that influenza imposes a significant disease burden and economic costs on high-risk populations in low- and middle-income countries (LMICs), including Bangladesh, influenza vaccination has not received adequate attention in these regions until 2023 [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR82">82</xref>]. Similar to other low- and middle-income countries (LMICs), Bangladesh has experienced low adoption of influenza vaccines and a dearth of country-specific evidence regarding the effectiveness and cost-effectiveness of vaccination programs targeting high-risk groups [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR16">16</xref>].</p>
              <p id="Par74">In order to address the existing data gaps and support the development of a national influenza vaccination policy, the present study aims to evaluate the acceptability, cost-effectiveness, and necessary infrastructure for implementing a seasonal influenza vaccination program that targets explicitly high-risk populations in Bangladesh. The study will be carried out in three tertiary-level teaching hospitals situated in Bangladesh. In this study, we will employ the health belief model (HBM) framework to assess the acceptability, health beliefs, barriers, and intention to receive the influenza vaccine. To assess the efficacy of the influenza vaccination, we will offer the vaccine for free to study participants and then follow up with them biweekly for one year. We will also employ a deterministic Markov decision-analytic model to evaluate the cost-effectiveness of facility-based vaccination in Bangladesh.</p>
              <p id="Par75">In early 2019, the WHO published a Global Influenza Strategy for the period of 2019–2030 with the aim of safeguarding individuals across all nations against the potential risks posed by influenza [<xref ref-type="bibr" rid="CR83">83</xref>]. In order to effectively prevent and control influenza and attain a significant level of progress by the year 2030, it is imperative to prioritize the promotion and implementation of influenza vaccination strategies among high-risk populations, particularly in low- and middle-income countries such as Bangladesh.</p>
              <p id="Par76">One notable limitation of this study is its exclusive focus on two tertiary-level healthcare facilities. In future research, it is strongly recommended to broaden the scope by incorporating a more diverse range of healthcare facilities to enhance the generalizability of the findings.</p>
              <p id="Par77">This study protocol will provide useful data on high-risk groups’ willingness to receive the influenza vaccine, including barriers to vaccination, and will assess whether a facility-based vaccination is cost-effective. The study’s key findings will provide the NITAG and IEDCR, MoH&amp;FW government of Bangladesh, with country-specific data on the cost-effectiveness of facility-based influenza vaccination, supporting advocacy for a national program targeting high-risk groups. Secondly, the data obtained from this study will also help to inform effective interventions targeting high-risk groups for improving influenza vaccine uptake utilizing evidence generated from a vaccine acceptance survey. Finally, the study findings will assist policymakers in designing and implementing a viable influenza vaccination program by estimating the direct and indirect costs of such a programme.</p>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn>
                <p>
                  <bold>Publisher’s Note</bold>
                </p>
                <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
            </fn-group>
            <ack>
              <title>Acknowledgements</title>
              <p>We are grateful to William Bill Davis and Susan Kaydos-Daniels (Neely) for providing technical support. We acknowledge the contribution of the International Centre for Diarrheal Diseases Research, Bangladesh (icddr,b), for organizational support with the work. icddr,b is grateful to the Governments of Bangladesh, and Canada for providing core/unrestricted support.</p>
            </ack>
            <notes notes-type="author-contribution">
              <title>Author contributions</title>
              <p>ZH conceptualized the research question. The study was designed by ZH, MAAJB, MH, TS, FC, MR, MAH, SRP, MTH and MR. The original protocol was written by ZH, MAAJB, and MH. ZH, MAAJB, FC, and MH responded to the external reviewer’s comments. ZH, MAAJB, FC, MR, MR and MH, developed data collection tools. ZH, MAAJB wrote the manuscripts. ZH, MAAJB, MR, HRS, ASP, AMI, MAH, SRP, MTH, MH, MR, TS, FC reviewed the manuscript. All authors read and approved the final manuscript.</p>
            </notes>
            <notes notes-type="funding-information">
              <title>Funding</title>
              <p>The study was funded by the US Centers for Disease Control and Prevention (CDC), Atlanta (<ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/">https://www.cdc.gov/</ext-link>). The Grant No is GR-01846 (cooperative agreement number U01GH002259). The funder had no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data, or decision to submit results.</p>
            </notes>
            <notes notes-type="data-availability">
              <title>Data availability</title>
              <p>Not applicable (For the purposes of this article, data sharing does not apply as no datasets have been produced or analyzed).</p>
            </notes>
            <notes>
              <title>Declarations</title>
              <notes id="FPar2" notes-type="COI-statement">
                <title>Ethics approval and consent to participate</title>
                <p id="Par78">The institutional review board (IRB) of the International Centre for Diarrhoeal Disease Research, Bangladesh (<ext-link ext-link-type="uri" xlink:href="https://www.icddrb.org/">https://www.icddrb.org/</ext-link>) reviewed and approved the study protocol (PR-23014). The Institutional Review Board at the Centers for Disease Control and Prevention (Atlanta, GA, USA) relied on the International Centre for Diarrhoeal Disease Research, Bangladesh (<ext-link ext-link-type="uri" xlink:href="https://www.icddrb.org/">https://www.icddrb.org/</ext-link>) approval. We will obtain written informed consent from all study participants. The study team will provide detailed oral and written information in the local language (Bangla) on research aims, objectives, risks and benefits of participation, maintaining confidentiality, the right not to participate and/or withdraw conflicts of interest, and compensation. After being reminded that their participation is entirely voluntary and that any information they provide will be kept strictly confidential, participants will be asked to sign the consent form.</p>
              </notes>
              <notes id="FPar3">
                <title>Consent for publication</title>
                <p id="Par79">Not Applicable.</p>
              </notes>
              <notes id="FPar4">
                <title>Disclaimer</title>
                <p id="Par80">The findings and conclusions in this report are those of the authors and do not necessarily represent the US Centers for Disease Control and Prevention official position.</p>
              </notes>
              <notes id="FPar1" notes-type="COI-statement">
                <title>Competing interests</title>
                <p id="Par81">The authors declare no competing interests.</p>
              </notes>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nichol</surname>
                      <given-names>KL</given-names>
                    </name>
                  </person-group>
                  <article-title>Cost-effectiveness and socio-economic aspects of childhood influenza vaccination</article-title>
                  <source>Vaccine</source>
                  <year>2011</year>
                  <volume>29</volume>
                  <issue>43</issue>
                  <fpage>7554</fpage>
                  <lpage>8</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.vaccine.2011.08.015</pub-id>
                  <?supplied-pmid 21820477?>
                  <pub-id pub-id-type="pmid">21820477</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Simonsen</surname>
                      <given-names>L</given-names>
                    </name>
                  </person-group>
                  <article-title>The global impact of influenza on morbidity and mortality</article-title>
                  <source>Vaccine</source>
                  <year>1999</year>
                  <volume>17</volume>
                  <fpage>3</fpage>
                  <lpage>S10</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0264-410X(99)00099-7</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bhuiyan</surname>
                      <given-names>MU</given-names>
                    </name>
                    <name>
                      <surname>Luby</surname>
                      <given-names>SP</given-names>
                    </name>
                    <name>
                      <surname>Alamgir</surname>
                      <given-names>NI</given-names>
                    </name>
                    <name>
                      <surname>Homaira</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Mamun</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>Khan</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Abedin</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Sturm-Ramirez</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Gurley</surname>
                      <given-names>ES</given-names>
                    </name>
                    <name>
                      <surname>Zaman</surname>
                      <given-names>RU</given-names>
                    </name>
                  </person-group>
                  <article-title>Economic burden of influenza‐associated hospitalizations and outpatient visits in B angladesh during 2010</article-title>
                  <source>Influenza Other Respir Viruses</source>
                  <year>2014</year>
                  <volume>8</volume>
                  <issue>4</issue>
                  <fpage>406</fpage>
                  <lpage>13</lpage>
                  <pub-id pub-id-type="doi">10.1111/irv.12254</pub-id>
                  <?supplied-pmid 24750586?>
                  <pub-id pub-id-type="pmid">24750586</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <mixed-citation publication-type="other">World Health Organization. WHO launches new global influenza strategy. Available at: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/news/item/11-03-2019-who-launches-new-global-influenza-strategy">https://www.who.int/news/item/11-03-2019-who-launches-new-global-influenza-strategy</ext-link>. Accessed 27 January 2022. [ ].</mixed-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Coleman</surname>
                      <given-names>BL</given-names>
                    </name>
                    <name>
                      <surname>Fadel</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Fitzpatrick</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Thomas</surname>
                      <given-names>SM</given-names>
                    </name>
                  </person-group>
                  <article-title>Risk factors for serious outcomes associated with influenza illness in high-versus low‐and middle‐income countries: systematic literature review and meta‐analysis</article-title>
                  <source>Influenza Other Respir Viruses</source>
                  <year>2018</year>
                  <volume>12</volume>
                  <issue>1</issue>
                  <fpage>22</fpage>
                  <lpage>9</lpage>
                  <pub-id pub-id-type="doi">10.1111/irv.12504</pub-id>
                  <?supplied-pmid 29197154?>
                  <pub-id pub-id-type="pmid">29197154</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <mixed-citation publication-type="other">Mertz D, Kim TH, Johnstone J, Lam P-P, Kuster SP, Fadel SA, Tran D, Fernandez E, Bhatnagar N, Loeb M. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. BMJ 2013, 347.</mixed-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Organization WH</surname>
                    </name>
                  </person-group>
                  <article-title>Vaccines against influenza WHO position paper—November 2012</article-title>
                  <source>Wkly Epidemiol Record = Relevé épidémiologique Hebdomadaire</source>
                  <year>2012</year>
                  <volume>87</volume>
                  <issue>47</issue>
                  <fpage>461</fpage>
                  <lpage>76</lpage>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hirve</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Lambach</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Paget</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Vandemaele</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Fitzner</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>W</given-names>
                    </name>
                  </person-group>
                  <article-title>Seasonal influenza vaccine policy, use and effectiveness in the tropics and subtropics–a systematic literature review</article-title>
                  <source>Influenza Other Respir Viruses</source>
                  <year>2016</year>
                  <volume>10</volume>
                  <issue>4</issue>
                  <fpage>254</fpage>
                  <lpage>67</lpage>
                  <pub-id pub-id-type="doi">10.1111/irv.12374</pub-id>
                  <?supplied-pmid 26842617?>
                  <pub-id pub-id-type="pmid">26842617</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ortiz</surname>
                      <given-names>JR</given-names>
                    </name>
                    <name>
                      <surname>Perut</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Dumolard</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Wijesinghe</surname>
                      <given-names>PR</given-names>
                    </name>
                    <name>
                      <surname>Jorgensen</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Ropero</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Danovaro-Holliday</surname>
                      <given-names>MC</given-names>
                    </name>
                    <name>
                      <surname>Heffelfinger</surname>
                      <given-names>JD</given-names>
                    </name>
                    <name>
                      <surname>Tevi-Benissan</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Teleb</surname>
                      <given-names>NA</given-names>
                    </name>
                  </person-group>
                  <article-title>A global review of national influenza immunization policies: analysis of the 2014 WHO/UNICEF Joint reporting form on immunization</article-title>
                  <source>Vaccine</source>
                  <year>2016</year>
                  <volume>34</volume>
                  <issue>45</issue>
                  <fpage>5400</fpage>
                  <lpage>5</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.vaccine.2016.07.045</pub-id>
                  <?supplied-pmid 27646030?>
                  <pub-id pub-id-type="pmid">27646030</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <mixed-citation publication-type="other">Hirve S, Organization WH. Seasonal influenza vaccine use in low and middle income countries in the tropics and subtropics: a systematic review. World Health Organization; 2015.</mixed-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sibanda</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Meyer</surname>
                      <given-names>JC</given-names>
                    </name>
                    <name>
                      <surname>Godman</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Burnett</surname>
                      <given-names>RJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Low influenza vaccine uptake by healthcare workers caring for the elderly in South African old age homes and primary healthcare facilities</article-title>
                  <source>BMC Public Health</source>
                  <year>2023</year>
                  <volume>23</volume>
                  <issue>1</issue>
                  <fpage>1</fpage>
                  <lpage>13</lpage>
                  <pub-id pub-id-type="doi">10.1186/s12889-022-14926-8</pub-id>
                  <pub-id pub-id-type="pmid">36624437</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chen</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>Q</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Gu</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Zhou</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Cao</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Wu</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Liang</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Zheng</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Xian</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Factors associated with influenza vaccination coverage and willingness in the elderly with chronic diseases in Shenzhen, China</article-title>
                  <source>Hum Vaccines Immunotherapeutics</source>
                  <year>2022</year>
                  <volume>18</volume>
                  <issue>6</issue>
                  <fpage>2133912</fpage>
                  <pub-id pub-id-type="doi">10.1080/21645515.2022.2133912</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wiley</surname>
                      <given-names>KE</given-names>
                    </name>
                    <name>
                      <surname>Massey</surname>
                      <given-names>PD</given-names>
                    </name>
                    <name>
                      <surname>Cooper</surname>
                      <given-names>SC</given-names>
                    </name>
                    <name>
                      <surname>Wood</surname>
                      <given-names>NJ</given-names>
                    </name>
                    <name>
                      <surname>Ho</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Quinn</surname>
                      <given-names>HE</given-names>
                    </name>
                    <name>
                      <surname>Leask</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Uptake of influenza vaccine by pregnant women: a cross-sectional survey</article-title>
                  <source>Med J Aust</source>
                  <year>2013</year>
                  <volume>198</volume>
                  <issue>7</issue>
                  <fpage>373</fpage>
                  <lpage>5</lpage>
                  <pub-id pub-id-type="doi">10.5694/mja12.11849</pub-id>
                  <?supplied-pmid 23581957?>
                  <pub-id pub-id-type="pmid">23581957</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Marrie</surname>
                      <given-names>RA</given-names>
                    </name>
                    <name>
                      <surname>Walld</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Bolton</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Sareen</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Patten</surname>
                      <given-names>SB</given-names>
                    </name>
                    <name>
                      <surname>Singer</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Lix</surname>
                      <given-names>LM</given-names>
                    </name>
                    <name>
                      <surname>Hitchon</surname>
                      <given-names>CA</given-names>
                    </name>
                    <name>
                      <surname>Marriott</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>El-Gabalawy</surname>
                      <given-names>R</given-names>
                    </name>
                  </person-group>
                  <article-title>Uptake of influenza vaccination among persons with inflammatory bowel disease, multiple sclerosis or rheumatoid arthritis: a population-based matched cohort study</article-title>
                  <source>Can Med Association Open Access J</source>
                  <year>2021</year>
                  <volume>9</volume>
                  <issue>2</issue>
                  <fpage>E510</fpage>
                  <lpage>21</lpage>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ortiz</surname>
                      <given-names>JR</given-names>
                    </name>
                    <name>
                      <surname>Neuzil</surname>
                      <given-names>KM</given-names>
                    </name>
                  </person-group>
                  <article-title>Influenza immunization in low-and middle-income countries: preparing for next-generation influenza vaccines</article-title>
                  <source>J Infect Dis</source>
                  <year>2019</year>
                  <volume>219</volume>
                  <issue>Supplement1</issue>
                  <fpage>97</fpage>
                  <lpage>S106</lpage>
                  <pub-id pub-id-type="doi">10.1093/infdis/jiz024</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ott</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Klein Breteler</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Tam</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Hutubessy</surname>
                      <given-names>RC</given-names>
                    </name>
                    <name>
                      <surname>Jit</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>de Boer</surname>
                      <given-names>MR</given-names>
                    </name>
                  </person-group>
                  <article-title>Influenza vaccines in low and middle income countries: a systematic review of economic evaluations</article-title>
                  <source>Hum Vaccines Immunotherapeutics</source>
                  <year>2013</year>
                  <volume>9</volume>
                  <issue>7</issue>
                  <fpage>1500</fpage>
                  <lpage>11</lpage>
                  <pub-id pub-id-type="doi">10.4161/hv.24704</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ahmed</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Aleem</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Roguski</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Abedin</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Islam</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Alam</surname>
                      <given-names>KF</given-names>
                    </name>
                    <name>
                      <surname>Gurley</surname>
                      <given-names>ES</given-names>
                    </name>
                    <name>
                      <surname>Rahman</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Azziz-Baumgartner</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Homaira</surname>
                      <given-names>N</given-names>
                    </name>
                  </person-group>
                  <article-title>Estimates of seasonal influenza‐associated mortality in Bangladesh, 2010‐2012</article-title>
                  <source>Influenza Other Respir Viruses</source>
                  <year>2018</year>
                  <volume>12</volume>
                  <issue>1</issue>
                  <fpage>65</fpage>
                  <lpage>71</lpage>
                  <pub-id pub-id-type="doi">10.1111/irv.12490</pub-id>
                  <?supplied-pmid 29197174?>
                  <pub-id pub-id-type="pmid">29197174</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Azziz-Baumgartner</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Alamgir</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Rahman</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Homaira</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Sohel</surname>
                      <given-names>BM</given-names>
                    </name>
                    <name>
                      <surname>Sharker</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Zaman</surname>
                      <given-names>RU</given-names>
                    </name>
                    <name>
                      <surname>Dee</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Gurley</surname>
                      <given-names>ES</given-names>
                    </name>
                    <name>
                      <surname>Mamun</surname>
                      <given-names>AA</given-names>
                    </name>
                  </person-group>
                  <article-title>Incidence of influenza-like illness and severe acute respiratory infection during three influenza seasons in Bangladesh, 2008–2010</article-title>
                  <source>Bull World Health Organ</source>
                  <year>2012</year>
                  <volume>90</volume>
                  <fpage>12</fpage>
                  <lpage>9</lpage>
                  <pub-id pub-id-type="doi">10.2471/BLT.11.090209</pub-id>
                  <?supplied-pmid 22271960?>
                  <pub-id pub-id-type="pmid">22271960</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hassan</surname>
                      <given-names>MZ</given-names>
                    </name>
                    <name>
                      <surname>Shirin</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Rahman</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Alamgir</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Jahan</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Al Jubayer Biswas</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Khan</surname>
                      <given-names>SH</given-names>
                    </name>
                    <name>
                      <surname>Basher</surname>
                      <given-names>MAK</given-names>
                    </name>
                    <name>
                      <surname>Islam</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Hussain</surname>
                      <given-names>K</given-names>
                    </name>
                  </person-group>
                  <article-title>Seasonal influenza vaccine uptake among healthcare workers in tertiary care hospitals, Bangladesh: study protocol for influenza vaccine supply and awareness intervention</article-title>
                  <source>BMC Public Health</source>
                  <year>2022</year>
                  <volume>22</volume>
                  <issue>1</issue>
                  <fpage>1819</fpage>
                  <pub-id pub-id-type="doi">10.1186/s12889-022-14182-w</pub-id>
                  <?supplied-pmid 36153529?>
                  <pub-id pub-id-type="pmid">36153529</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Organization</surname>
                      <given-names>WH</given-names>
                    </name>
                  </person-group>
                  <article-title>Health conditions for travellers to Saudi Arabia pilgrimage to Mecca (Hajj)</article-title>
                  <source>Wkly Epidemiol Record = Relevé épidémiologique Hebdomadaire</source>
                  <year>2005</year>
                  <volume>80</volume>
                  <issue>49–50</issue>
                  <fpage>431</fpage>
                  <lpage>2</lpage>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>BARBERIS</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>MYLES</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Ault</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Bragazzi</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Martini</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>History and evolution of influenza control through vaccination: from the first monovalent vaccine to universal vaccines</article-title>
                  <source>J Prev Med Hyg</source>
                  <year>2016</year>
                  <volume>57</volume>
                  <issue>3</issue>
                  <fpage>E115</fpage>
                  <?supplied-pmid 27980374?>
                  <pub-id pub-id-type="pmid">27980374</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gasparini</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Amicizia</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Lai</surname>
                      <given-names>PL</given-names>
                    </name>
                    <name>
                      <surname>Bragazzi</surname>
                      <given-names>NL</given-names>
                    </name>
                    <name>
                      <surname>Panatto</surname>
                      <given-names>D</given-names>
                    </name>
                  </person-group>
                  <article-title>Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part I: Influenza life-cycle and currently available drugs</article-title>
                  <source>J Prev Med Hyg</source>
                  <year>2014</year>
                  <volume>55</volume>
                  <issue>3</issue>
                  <fpage>69</fpage>
                  <?supplied-pmid 25902573?>
                  <pub-id pub-id-type="pmid">25902573</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Peasah</surname>
                      <given-names>SK</given-names>
                    </name>
                    <name>
                      <surname>Azziz-Baumgartner</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Breese</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Meltzer</surname>
                      <given-names>MI</given-names>
                    </name>
                    <name>
                      <surname>Widdowson</surname>
                      <given-names>M-A</given-names>
                    </name>
                  </person-group>
                  <article-title>Influenza cost and cost-effectiveness studies globally–a review</article-title>
                  <source>Vaccine</source>
                  <year>2013</year>
                  <volume>31</volume>
                  <issue>46</issue>
                  <fpage>5339</fpage>
                  <lpage>48</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.vaccine.2013.09.013</pub-id>
                  <?supplied-pmid 24055351?>
                  <pub-id pub-id-type="pmid">24055351</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <mixed-citation publication-type="other">Dilokthornsakul P, Lan LM, Thakkinstian A, Hutubessy R, Lambach P, Chaiyakunapruk N. Economic evaluation of seasonal influenza vaccination in elderly and health workers: a systematic review and meta-analysis. EClinicalMedicine 2022, 47.</mixed-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zaman</surname>
                      <given-names>RU</given-names>
                    </name>
                    <name>
                      <surname>Alamgir</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Rahman</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Azziz-Baumgartner</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Gurley</surname>
                      <given-names>ES</given-names>
                    </name>
                    <name>
                      <surname>Sharker</surname>
                      <given-names>MAY</given-names>
                    </name>
                    <name>
                      <surname>Brooks</surname>
                      <given-names>WA</given-names>
                    </name>
                    <name>
                      <surname>Azim</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Fry</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Lindstrom</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>Influenza in outpatient ILI case-patients in national hospital-based surveillance, Bangladesh, 2007–2008</article-title>
                  <source>PLoS ONE</source>
                  <year>2009</year>
                  <volume>4</volume>
                  <issue>12</issue>
                  <fpage>e8452</fpage>
                  <pub-id pub-id-type="doi">10.1371/journal.pone.0008452</pub-id>
                  <?supplied-pmid 20041114?>
                  <pub-id pub-id-type="pmid">20041114</pub-id>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <mixed-citation publication-type="other">Bangladesh Bureau of Statistics.Statistical Yearbook of Bangladesh. 2020. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.bbs.gov.bd/site/page/29855dc1-f2b4-4dc0-9073-f692361112da/Statistical-Yearbook">http://www.bbs.gov.bd/site/page/29855dc1-f2b4-4dc0-9073-f692361112da/Statistical-Yearbook</ext-link>. Accessed 27 January 2022. In.</mixed-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <mixed-citation publication-type="other">Incepta Vaccine Ltd.Influvax. Available at: <ext-link ext-link-type="uri" xlink:href="http://inceptavaccine.com/product-details.php?pid=influvax-">http://inceptavaccine.com/product-details.php?pid=influvax</ext-link>. Accessed 16 November 2022.</mixed-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <mixed-citation publication-type="other">Sanofi.Vaxigrip. Available at: <ext-link ext-link-type="uri" xlink:href="https://www.mims.com/philippines/drug/info/vaxigrip?type=full">https://www.mims.com/philippines/drug/info/vaxigrip?type=full</ext-link>. Accessed 16 November 2022.</mixed-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <mixed-citation publication-type="other">Directorate General of Health Services (DGHS). Ministry of Health and Family Welfare (MOHFS). Local Health Bulletin;Khulna Medical College Hospital. Available at: <ext-link ext-link-type="uri" xlink:href="http://103.247.238.81/webportal/pages/rtlhb.php?type=5">http://103.247.238.81/webportal/pages/rtlhb.php?type=5</ext-link> (Access date, November 11, 2022).</mixed-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <mixed-citation publication-type="other">Directorate General of Health Services (DGHS). Ministry of Health and Family Welfare (MOHFS). Local Health Bulletin. Rajshahi Medical College, Rajshahi. Available at: <ext-link ext-link-type="uri" xlink:href="http://103.247.238.81/webportal/pages/rtlhb.php?type=5">http://103.247.238.81/webportal/pages/rtlhb.php?type=5</ext-link> (Access date, November 11, 2022).</mixed-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <mixed-citation publication-type="other">Maldonado YA, O’Leary ST, Ardura MI, Banerjee R, Bryant KA, Campbell JD, Caserta MT, John CC, Gerber JS, Kourtis AP. Recommendations for prevention and control of influenza in children, 2021–2022. Pediatrics 2021, 148(4).</mixed-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <mixed-citation publication-type="other">World Health Organization. Summary of WHO position papers - recommendations for routine immunization.Available at: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/immunization/policy/Immunization_routine_table1.pdf">https://www.who.int/immunization/policy/Immunization_routine_table1.pdf</ext-link>. Accessed 27 January 2022. In.</mixed-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <mixed-citation publication-type="other">Jalalabad Ragib Rabeya Medical College &amp;, Hospital S. Access date, November 11,. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.jrrmc.edu.bd/">http://www.jrrmc.edu.bd/</ext-link> (2022).</mixed-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Research NIoP</surname>
                    </name>
                  </person-group>
                  <source>Training - NIPORT, Health Mo, Family Welfare, ICF: Bangladesh Demographic and Health Survey 2017-18. In. Dhaka</source>
                  <year>2020</year>
                  <publisher-loc>Bangladesh</publisher-loc>
                  <publisher-name>NIPORT/ICF</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR35">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sultana</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Mahumud</surname>
                      <given-names>RA</given-names>
                    </name>
                    <name>
                      <surname>Sarker</surname>
                      <given-names>AR</given-names>
                    </name>
                  </person-group>
                  <article-title>Burden of chronic illness and associated disabilities in Bangladesh: evidence from the Household Income and Expenditure Survey</article-title>
                  <source>Chronic Dis Translational Med</source>
                  <year>2017</year>
                  <volume>3</volume>
                  <issue>2</issue>
                  <fpage>112</fpage>
                  <lpage>22</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.cdtm.2017.02.001</pub-id>
                </element-citation>
              </ref>
              <ref id="CR36">
                <label>36.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Champion</surname>
                      <given-names>VL</given-names>
                    </name>
                    <name>
                      <surname>Skinner</surname>
                      <given-names>CS</given-names>
                    </name>
                  </person-group>
                  <article-title>The health belief model</article-title>
                  <source>Health Behav Health Education: Theory Res Pract</source>
                  <year>2008</year>
                  <volume>4</volume>
                  <fpage>45</fpage>
                  <lpage>65</lpage>
                </element-citation>
              </ref>
              <ref id="CR37">
                <label>37.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cheney</surname>
                      <given-names>MK</given-names>
                    </name>
                    <name>
                      <surname>John</surname>
                      <given-names>R</given-names>
                    </name>
                  </person-group>
                  <article-title>Underutilization of influenza vaccine: a test of the health belief model</article-title>
                  <source>Sage Open</source>
                  <year>2013</year>
                  <volume>3</volume>
                  <issue>2</issue>
                  <fpage>2158244013484732</fpage>
                  <pub-id pub-id-type="doi">10.1177/2158244013484732</pub-id>
                </element-citation>
              </ref>
              <ref id="CR38">
                <label>38.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mahmud</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Kabir</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Rahman</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Alradie-Mohamed</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Vinnakota</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Al-Mohaimeed</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>The health belief model predicts intention to receive the covid-19 vaccine in Saudi Arabia: results from a cross-sectional survey</article-title>
                  <source>Vaccines</source>
                  <year>2021</year>
                  <volume>9</volume>
                  <issue>8</issue>
                  <fpage>864</fpage>
                  <pub-id pub-id-type="doi">10.3390/vaccines9080864</pub-id>
                  <?supplied-pmid 34451991?>
                  <pub-id pub-id-type="pmid">34451991</pub-id>
                </element-citation>
              </ref>
              <ref id="CR39">
                <label>39.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mo</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Lau</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Influenza vaccination uptake and associated factors among elderly population in Hong Kong: the application of the Health Belief Model</article-title>
                  <source>Health Educ Res</source>
                  <year>2015</year>
                  <volume>30</volume>
                  <issue>5</issue>
                  <fpage>706</fpage>
                  <lpage>18</lpage>
                  <pub-id pub-id-type="doi">10.1093/her/cyv038</pub-id>
                  <?supplied-pmid 26336905?>
                  <pub-id pub-id-type="pmid">26336905</pub-id>
                </element-citation>
              </ref>
              <ref id="CR40">
                <label>40.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nexøe</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Kragstrup</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Søgaard</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Decision on influenza vaccination among the elderly: a questionnaire study based on the Health Belief Model and the Multidimensional Locus of Control Theory</article-title>
                  <source>Scand J Prim Health Care</source>
                  <year>1999</year>
                  <volume>17</volume>
                  <issue>2</issue>
                  <fpage>105</fpage>
                  <lpage>10</lpage>
                  <pub-id pub-id-type="doi">10.1080/028134399750002737</pub-id>
                  <?supplied-pmid 10439494?>
                  <pub-id pub-id-type="pmid">10439494</pub-id>
                </element-citation>
              </ref>
              <ref id="CR41">
                <label>41.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hu</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Liang</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>Y</given-names>
                    </name>
                  </person-group>
                  <article-title>Seasonal influenza vaccine acceptance among pregnant women in Zhejiang Province, China: evidence based on health belief model</article-title>
                  <source>Int J Environ Res Public Health</source>
                  <year>2017</year>
                  <volume>14</volume>
                  <issue>12</issue>
                  <fpage>1551</fpage>
                  <pub-id pub-id-type="doi">10.3390/ijerph14121551</pub-id>
                  <?supplied-pmid 29232882?>
                  <pub-id pub-id-type="pmid">29232882</pub-id>
                </element-citation>
              </ref>
              <ref id="CR42">
                <label>42.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ortega-Sanchez</surname>
                      <given-names>IR</given-names>
                    </name>
                    <name>
                      <surname>Mott</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Kittikraisak</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Khanthamaly</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>McCarron</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Keokhonenang</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Ounaphom</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Pathammavong</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Phounphenghack</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Sayamoungkhoun</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Cost-effectiveness of seasonal influenza vaccination in pregnant women, healthcare workers and adults &gt; = 60 years of age in Lao people’s Democratic Republic</article-title>
                  <source>Vaccine</source>
                  <year>2021</year>
                  <volume>39</volume>
                  <issue>52</issue>
                  <fpage>7633</fpage>
                  <lpage>45</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.vaccine.2021.11.011</pub-id>
                  <?supplied-pmid 34802790?>
                  <pub-id pub-id-type="pmid">34802790</pub-id>
                </element-citation>
              </ref>
              <ref id="CR43">
                <label>43.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Edoka</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Kohli-Lynch</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Fraser</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Hofman</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Tempia</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>McMorrow</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Ramkrishna</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Lambach</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Hutubessy</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Cohen</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>A cost-effectiveness analysis of South Africa’s seasonal influenza vaccination programme</article-title>
                  <source>Vaccine</source>
                  <year>2021</year>
                  <volume>39</volume>
                  <issue>2</issue>
                  <fpage>412</fpage>
                  <lpage>22</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.vaccine.2020.11.028</pub-id>
                  <?supplied-pmid 33272702?>
                  <pub-id pub-id-type="pmid">33272702</pub-id>
                </element-citation>
              </ref>
              <ref id="CR44">
                <label>44.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Costantino</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Vitale</surname>
                      <given-names>F</given-names>
                    </name>
                  </person-group>
                  <article-title>Influenza vaccination in high-risk groups: a revision of existing guidelines and rationale for an evidence-based preventive strategy</article-title>
                  <source>J Prev Med Hyg</source>
                  <year>2016</year>
                  <volume>57</volume>
                  <issue>1</issue>
                  <fpage>E13</fpage>
                  <?supplied-pmid 27346934?>
                  <pub-id pub-id-type="pmid">27346934</pub-id>
                </element-citation>
              </ref>
              <ref id="CR45">
                <label>45.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Arsenović</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Trajković</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Pekmezović</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Gazibara</surname>
                      <given-names>T</given-names>
                    </name>
                  </person-group>
                  <article-title>Validity of the Health Belief Model Applied to Influenza among people with chronic diseases: is it time to develop a new knowledge domain?</article-title>
                  <source>PLoS ONE</source>
                  <year>2022</year>
                  <volume>17</volume>
                  <issue>9</issue>
                  <fpage>e0274739</fpage>
                  <pub-id pub-id-type="doi">10.1371/journal.pone.0274739</pub-id>
                  <?supplied-pmid 36108085?>
                  <pub-id pub-id-type="pmid">36108085</pub-id>
                </element-citation>
              </ref>
              <ref id="CR46">
                <label>46.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Trent</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Salmon</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>MacIntyre</surname>
                      <given-names>CR</given-names>
                    </name>
                  </person-group>
                  <article-title>Using the health belief model to identify barriers to seasonal influenza vaccination among Australian adults in 2019</article-title>
                  <source>Influenza Other Respir Viruses</source>
                  <year>2021</year>
                  <volume>15</volume>
                  <issue>5</issue>
                  <fpage>678</fpage>
                  <lpage>87</lpage>
                  <pub-id pub-id-type="doi">10.1111/irv.12843</pub-id>
                  <?supplied-pmid 33586871?>
                  <pub-id pub-id-type="pmid">33586871</pub-id>
                </element-citation>
              </ref>
              <ref id="CR47">
                <label>47.</label>
                <mixed-citation publication-type="other">WHO.WHO surveillance case definitions for ILI and SARI. Available at: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/teams/global-influenza-programme/surveillance-and-monitoring/case-definitions-for-ili-and-sari#:~:text=SARI%20case%20definition,within%20the%20last%2010%20days">https://www.who.int/teams/global-influenza-programme/surveillance-and-monitoring/case-definitions-for-ili-and-sari#:~:text=SARI%20case%20definition,within%20the%20last%2010%20days</ext-link>. Accessed 16 November 2022.</mixed-citation>
              </ref>
              <ref id="CR48">
                <label>48.</label>
                <mixed-citation publication-type="other">World Health Organization. Information sheet: Observed rate of vaccine reactions, influenza vaccine. Available at:<ext-link ext-link-type="uri" xlink:href="https://www.who.int/vaccine_safety/initiative/tools/Influenza_Vaccine_rates_information_sheet.pdf">https://www.who.int/vaccine_safety/initiative/tools/Influenza_Vaccine_rates_information_sheet.pdf</ext-link>. Accessed 28 January 2022. [ ].</mixed-citation>
              </ref>
              <ref id="CR49">
                <label>49.</label>
                <mixed-citation publication-type="other">World Health Organization. Global health estimates: Leading causes of DALYs. Available at:<ext-link ext-link-type="uri" xlink:href="https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/global-health-estimates-leading-causes-of-dalys">https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/global-health-estimates-leading-causes-of-dalys</ext-link>. Accessed 6 February 2022. [ ].</mixed-citation>
              </ref>
              <ref id="CR50">
                <label>50.</label>
                <mixed-citation publication-type="other">World Health Organization. Global Health Estimates: Life expectancy and leading causes of death and disability. Available at: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates">https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates</ext-link>. Accessed 6 February 2022. [ ].</mixed-citation>
              </ref>
              <ref id="CR51">
                <label>51.</label>
                <mixed-citation publication-type="other">WHO methods and data sources for global burden of disease 2000–2019. Global Health Estimates Technical Paper WHO/DDI/DNA/GHE/2020.3.Geneva: World Health Organization; 2020 (<ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/gho-documents/global-health-estimates/GlobalBurden_method_2000_2019.pdf)">https://www.who.int/docs/default-source/gho-documents/global-health-estimates/GlobalBurden_method_2000_2019.pdf)</ext-link>.</mixed-citation>
              </ref>
              <ref id="CR52">
                <label>52.</label>
                <mixed-citation publication-type="other">World Population Prospects: The 2019 revision. New York: United Nations, Department of Economic and Social Affairs, Population Division.; 2019 (<ext-link ext-link-type="uri" xlink:href="https://esa.un.org/unpd/wpp/)">https://esa.un.org/unpd/wpp/)</ext-link>.</mixed-citation>
              </ref>
              <ref id="CR53">
                <label>53.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pecenka</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Parashar</surname>
                      <given-names>U</given-names>
                    </name>
                    <name>
                      <surname>Tate</surname>
                      <given-names>JE</given-names>
                    </name>
                    <name>
                      <surname>Khan</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Groman</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Chacko</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Shamsuzzaman</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Clark</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Atherly</surname>
                      <given-names>D</given-names>
                    </name>
                  </person-group>
                  <article-title>Impact and cost-effectiveness of rotavirus vaccination in Bangladesh</article-title>
                  <source>Vaccine</source>
                  <year>2017</year>
                  <volume>35</volume>
                  <issue>32</issue>
                  <fpage>3982</fpage>
                  <lpage>7</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.vaccine.2017.05.087</pub-id>
                  <?supplied-pmid 28623028?>
                  <pub-id pub-id-type="pmid">28623028</pub-id>
                </element-citation>
              </ref>
              <ref id="CR54">
                <label>54.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Van Minh</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>My</surname>
                      <given-names>NTT</given-names>
                    </name>
                    <name>
                      <surname>Jit</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Cervical cancer treatment costs and cost-effectiveness analysis of human papillomavirus vaccination in Vietnam: a PRIME modeling study</article-title>
                  <source>BMC Health Serv Res</source>
                  <year>2017</year>
                  <volume>17</volume>
                  <issue>1</issue>
                  <fpage>1</fpage>
                  <lpage>7</lpage>
                  <pub-id pub-id-type="pmid">28049468</pub-id>
                </element-citation>
              </ref>
              <ref id="CR55">
                <label>55.</label>
                <mixed-citation publication-type="other">Ministry of Health &amp; Family Welfare. Local Health bulletin.Available at:<ext-link ext-link-type="uri" xlink:href="http://103.247.238.81/webportal/pages/rtlhb_monthly_monitoring.php?type=50">http://103.247.238.81/webportal/pages/rtlhb_monthly_monitoring.php?type=50</ext-link>. Accessed 27 January 2022.</mixed-citation>
              </ref>
              <ref id="CR56">
                <label>56.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Biswas</surname>
                      <given-names>MAAJ</given-names>
                    </name>
                    <name>
                      <surname>Hassan</surname>
                      <given-names>MZ</given-names>
                    </name>
                    <name>
                      <surname>Monjur</surname>
                      <given-names>MR</given-names>
                    </name>
                    <name>
                      <surname>Islam</surname>
                      <given-names>MS</given-names>
                    </name>
                    <name>
                      <surname>Rahman</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Akhtar</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Chowdhury</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Banu</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Homaira</surname>
                      <given-names>N</given-names>
                    </name>
                  </person-group>
                  <article-title>Assessment of standard precaution related to infection prevention readiness of healthcare facilities in Bangladesh: findings from a national cross-sectional survey</article-title>
                  <source>Antimicrob Stewardship Healthc Epidemiol</source>
                  <year>2021</year>
                  <volume>1</volume>
                  <issue>1</issue>
                  <fpage>e52</fpage>
                  <pub-id pub-id-type="doi">10.1017/ash.2021.226</pub-id>
                </element-citation>
              </ref>
              <ref id="CR57">
                <label>57.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hassan</surname>
                      <given-names>MZ</given-names>
                    </name>
                    <name>
                      <surname>Monjur</surname>
                      <given-names>MR</given-names>
                    </name>
                    <name>
                      <surname>Biswas</surname>
                      <given-names>MAAJ</given-names>
                    </name>
                    <name>
                      <surname>Chowdhury</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Kafi</surname>
                      <given-names>MAH</given-names>
                    </name>
                    <name>
                      <surname>Braithwaite</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Jaffe</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Homaira</surname>
                      <given-names>N</given-names>
                    </name>
                  </person-group>
                  <article-title>Antibiotic use for acute respiratory infections among under-5 children in Bangladesh: a population-based survey</article-title>
                  <source>BMJ Global Health</source>
                  <year>2021</year>
                  <volume>6</volume>
                  <issue>4</issue>
                  <fpage>e004010</fpage>
                  <pub-id pub-id-type="doi">10.1136/bmjgh-2020-004010</pub-id>
                  <?supplied-pmid 33903174?>
                  <pub-id pub-id-type="pmid">33903174</pub-id>
                </element-citation>
              </ref>
              <ref id="CR58">
                <label>58.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Samir</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Hassan</surname>
                      <given-names>MZ</given-names>
                    </name>
                    <name>
                      <surname>Biswas</surname>
                      <given-names>MAAJ</given-names>
                    </name>
                    <name>
                      <surname>Chowdhury</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Akhtar</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Lingam</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Banu</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Homaira</surname>
                      <given-names>N</given-names>
                    </name>
                  </person-group>
                  <article-title>Antibiotic use for febrile illness among under-5 children in Bangladesh: a nationally representative sample survey</article-title>
                  <source>Antibiotics</source>
                  <year>2021</year>
                  <volume>10</volume>
                  <issue>10</issue>
                  <fpage>1153</fpage>
                  <pub-id pub-id-type="doi">10.3390/antibiotics10101153</pub-id>
                  <?supplied-pmid 34680735?>
                  <pub-id pub-id-type="pmid">34680735</pub-id>
                </element-citation>
              </ref>
              <ref id="CR59">
                <label>59.</label>
                <mixed-citation publication-type="other">Demicheli V, Jefferson T, Di Pietrantonj C, Ferroni E, Thorning S, Thomas RE, Rivetti A. Vaccines for preventing influenza in the elderly. Cochrane Database of Systematic Reviews 2018(2).</mixed-citation>
              </ref>
              <ref id="CR60">
                <label>60.</label>
                <mixed-citation publication-type="other">Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. <italic>Cochrane Database of Systematic Reviews</italic> 2008(2).</mixed-citation>
              </ref>
              <ref id="CR61">
                <label>61.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rolfes</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Goswami</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Sharmeen</surname>
                      <given-names>AT</given-names>
                    </name>
                    <name>
                      <surname>Yeasmin</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Parvin</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Nahar</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Rahman</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Barends</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Ahmed</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Rahman</surname>
                      <given-names>MZ</given-names>
                    </name>
                  </person-group>
                  <article-title>Efficacy of trivalent influenza vaccine against laboratory-confirmed influenza among young children in a randomized trial in Bangladesh</article-title>
                  <source>Vaccine</source>
                  <year>2017</year>
                  <volume>35</volume>
                  <issue>50</issue>
                  <fpage>6967</fpage>
                  <lpage>76</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.vaccine.2017.10.074</pub-id>
                  <?supplied-pmid 29100706?>
                  <pub-id pub-id-type="pmid">29100706</pub-id>
                </element-citation>
              </ref>
              <ref id="CR62">
                <label>62.</label>
                <mixed-citation publication-type="other">Organization WH. Methods for assessing influenza vaccination coverage in target groups. In.: World Health Organization. Regional Office for Europe; 2016.</mixed-citation>
              </ref>
              <ref id="CR63">
                <label>63.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Group</surname>
                      <given-names>SG-BST</given-names>
                    </name>
                  </person-group>
                  <article-title>Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome</article-title>
                  <source>The Lancet</source>
                  <year>1997</year>
                  <volume>349</volume>
                  <issue>9047</issue>
                  <fpage>225</fpage>
                  <lpage>30</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0140-6736(96)09095-2</pub-id>
                </element-citation>
              </ref>
              <ref id="CR64">
                <label>64.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>World Health</surname>
                      <given-names>O</given-names>
                    </name>
                  </person-group>
                  <article-title>Flutool plus: WHO seasonal influenza immunization costing tool (SIICT)</article-title>
                  <source>Pilot version 1.0 edn</source>
                  <year>2020</year>
                  <publisher-loc>Geneva</publisher-loc>
                  <publisher-name>World Health Organization</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR65">
                <label>65.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kadam</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Bhalerao</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>Sample size calculation</article-title>
                  <source>Int J Ayurveda Res</source>
                  <year>2010</year>
                  <volume>1</volume>
                  <issue>1</issue>
                  <fpage>55</fpage>
                  <pub-id pub-id-type="doi">10.4103/0974-7788.59946</pub-id>
                  <?supplied-pmid 20532100?>
                  <pub-id pub-id-type="pmid">20532100</pub-id>
                </element-citation>
              </ref>
              <ref id="CR66">
                <label>66.</label>
                <mixed-citation publication-type="other">Organization WH. Evaluation of influenza vaccine effectiveness: a guide to the design and interpretation of observational studies. 2017.</mixed-citation>
              </ref>
              <ref id="CR67">
                <label>67.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lemeshow</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Hosmer</surname>
                      <given-names>DW</given-names>
                    </name>
                    <name>
                      <surname>Klar</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Lwanga</surname>
                      <given-names>SK</given-names>
                    </name>
                    <name>
                      <surname>Organization</surname>
                      <given-names>WH</given-names>
                    </name>
                  </person-group>
                  <source>Adequacy of sample size in health studies</source>
                  <year>1990</year>
                  <publisher-loc>Chichester</publisher-loc>
                  <publisher-name>Wiley</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR68">
                <label>68.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Brooks</surname>
                      <given-names>WA</given-names>
                    </name>
                    <name>
                      <surname>Zaman</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Lewis</surname>
                      <given-names>KD</given-names>
                    </name>
                    <name>
                      <surname>Ortiz</surname>
                      <given-names>JR</given-names>
                    </name>
                    <name>
                      <surname>Goswami</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Feser</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Sharmeen</surname>
                      <given-names>AT</given-names>
                    </name>
                    <name>
                      <surname>Nahar</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Rahman</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Rahman</surname>
                      <given-names>MZ</given-names>
                    </name>
                  </person-group>
                  <article-title>Efficacy of a russian-backbone live attenuated influenza vaccine among young children in Bangladesh: a randomised, double-blind, placebo-controlled trial</article-title>
                  <source>The Lancet Global Health</source>
                  <year>2016</year>
                  <volume>4</volume>
                  <issue>12</issue>
                  <fpage>e946</fpage>
                  <lpage>54</lpage>
                  <pub-id pub-id-type="doi">10.1016/S2214-109X(16)30200-5</pub-id>
                  <?supplied-pmid 27746226?>
                  <pub-id pub-id-type="pmid">27746226</pub-id>
                </element-citation>
              </ref>
              <ref id="CR69">
                <label>69.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fell</surname>
                      <given-names>DB</given-names>
                    </name>
                    <name>
                      <surname>Azziz-Baumgartner</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Baker</surname>
                      <given-names>MG</given-names>
                    </name>
                    <name>
                      <surname>Batra</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Beauté</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Beutels</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Bhat</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Bhutta</surname>
                      <given-names>ZA</given-names>
                    </name>
                    <name>
                      <surname>Cohen</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>De Mucio</surname>
                      <given-names>B</given-names>
                    </name>
                  </person-group>
                  <article-title>Influenza epidemiology and immunization during pregnancy: final report of a World Health Organization working group</article-title>
                  <source>Vaccine</source>
                  <year>2017</year>
                  <volume>35</volume>
                  <issue>43</issue>
                  <fpage>5738</fpage>
                  <lpage>50</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.vaccine.2017.08.037</pub-id>
                  <?supplied-pmid 28867508?>
                  <pub-id pub-id-type="pmid">28867508</pub-id>
                </element-citation>
              </ref>
              <ref id="CR70">
                <label>70.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sullivan</surname>
                      <given-names>SG</given-names>
                    </name>
                    <name>
                      <surname>Price</surname>
                      <given-names>OH</given-names>
                    </name>
                    <name>
                      <surname>Regan</surname>
                      <given-names>AK</given-names>
                    </name>
                  </person-group>
                  <article-title>Burden, effectiveness and safety of influenza vaccines in elderly, paediatric and pregnant populations</article-title>
                  <source>Therapeutic Adv Vaccines Immunotherapy</source>
                  <year>2019</year>
                  <volume>7</volume>
                  <fpage>2515135519826481</fpage>
                  <pub-id pub-id-type="doi">10.1177/2515135519826481</pub-id>
                </element-citation>
              </ref>
              <ref id="CR71">
                <label>71.</label>
                <mixed-citation publication-type="other">Hair JF, Black WC, Babin BJ, Anderson RE. Multirative data analysis: A global perspective. In.: New Jersey: Pearson Prentice Hall; 2010.</mixed-citation>
              </ref>
              <ref id="CR72">
                <label>72.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mangtani</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Cumberland</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Hodgson</surname>
                      <given-names>CR</given-names>
                    </name>
                    <name>
                      <surname>Roberts</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Cutts</surname>
                      <given-names>FT</given-names>
                    </name>
                    <name>
                      <surname>Hall</surname>
                      <given-names>AJ</given-names>
                    </name>
                  </person-group>
                  <article-title>A cohort study of the effectiveness of influenza vaccine in older people, performed using the United Kingdom general practice research database</article-title>
                  <source>J Infect Dis</source>
                  <year>2004</year>
                  <volume>190</volume>
                  <issue>1</issue>
                  <fpage>1</fpage>
                  <lpage>10</lpage>
                  <pub-id pub-id-type="doi">10.1086/421274</pub-id>
                  <?supplied-pmid 15195237?>
                  <pub-id pub-id-type="pmid">15195237</pub-id>
                </element-citation>
              </ref>
              <ref id="CR73">
                <label>73.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Newall</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Jit</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Hutubessy</surname>
                      <given-names>R</given-names>
                    </name>
                  </person-group>
                  <article-title>Are current cost-effectiveness thresholds for low-and middle-income countries useful? Examples from the world of vaccines</article-title>
                  <source>PharmacoEconomics</source>
                  <year>2014</year>
                  <volume>32</volume>
                  <fpage>525</fpage>
                  <lpage>31</lpage>
                  <pub-id pub-id-type="doi">10.1007/s40273-014-0162-x</pub-id>
                  <?supplied-pmid 24791735?>
                  <pub-id pub-id-type="pmid">24791735</pub-id>
                </element-citation>
              </ref>
              <ref id="CR74">
                <label>74.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Newall</surname>
                      <given-names>AT</given-names>
                    </name>
                    <name>
                      <surname>Chaiyakunapruk</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Lambach</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Hutubessy</surname>
                      <given-names>RC</given-names>
                    </name>
                  </person-group>
                  <article-title>WHO guide on the economic evaluation of influenza vaccination</article-title>
                  <source>Influenza Other Respir Viruses</source>
                  <year>2018</year>
                  <volume>12</volume>
                  <issue>2</issue>
                  <fpage>211</fpage>
                  <lpage>9</lpage>
                  <pub-id pub-id-type="doi">10.1111/irv.12510</pub-id>
                  <?supplied-pmid 29024434?>
                  <pub-id pub-id-type="pmid">29024434</pub-id>
                </element-citation>
              </ref>
              <ref id="CR75">
                <label>75.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fesenfeld</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Hutubessy</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Jit</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review</article-title>
                  <source>Vaccine</source>
                  <year>2013</year>
                  <volume>31</volume>
                  <issue>37</issue>
                  <fpage>3786</fpage>
                  <lpage>804</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.vaccine.2013.06.060</pub-id>
                  <?supplied-pmid 23830973?>
                  <pub-id pub-id-type="pmid">23830973</pub-id>
                </element-citation>
              </ref>
              <ref id="CR76">
                <label>76.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tu</surname>
                      <given-names>H-AT</given-names>
                    </name>
                    <name>
                      <surname>Woerdenbag</surname>
                      <given-names>HJ</given-names>
                    </name>
                    <name>
                      <surname>Kane</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Rozenbaum</surname>
                      <given-names>MH</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>SC</given-names>
                    </name>
                    <name>
                      <surname>Postma</surname>
                      <given-names>MJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Economic evaluations of rotavirus immunization for developing countries: a review of the literature</article-title>
                  <source>Expert Rev Vaccines</source>
                  <year>2011</year>
                  <volume>10</volume>
                  <issue>7</issue>
                  <fpage>1037</fpage>
                  <lpage>51</lpage>
                  <pub-id pub-id-type="doi">10.1586/erv.11.65</pub-id>
                  <?supplied-pmid 21806398?>
                  <pub-id pub-id-type="pmid">21806398</pub-id>
                </element-citation>
              </ref>
              <ref id="CR77">
                <label>77.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McMorrow</surname>
                      <given-names>ML</given-names>
                    </name>
                    <name>
                      <surname>Tempia</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Walaza</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Treurnicht</surname>
                      <given-names>FK</given-names>
                    </name>
                    <name>
                      <surname>Ramkrishna</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Azziz-Baumgartner</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Madhi</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Cohen</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>Prioritization of risk groups for influenza vaccination in resource limited settings–A case study from South Africa</article-title>
                  <source>Vaccine</source>
                  <year>2019</year>
                  <volume>37</volume>
                  <issue>1</issue>
                  <fpage>25</fpage>
                  <lpage>33</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.vaccine.2018.11.048</pub-id>
                  <?supplied-pmid 30471956?>
                  <pub-id pub-id-type="pmid">30471956</pub-id>
                </element-citation>
              </ref>
              <ref id="CR78">
                <label>78.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>World Health</surname>
                      <given-names>O</given-names>
                    </name>
                  </person-group>
                  <source>Training for mid-level managers (MLM): module 1: cold chain, vaccines and safe-injection equipment management</source>
                  <year>2020</year>
                  <publisher-loc>Geneva</publisher-loc>
                  <publisher-name>World Health Organization</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR79">
                <label>79.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Organization</surname>
                      <given-names>WH</given-names>
                    </name>
                  </person-group>
                  <source>Guidelines for estimating costs of introducing new vaccines into the national immunization system</source>
                  <year>2002</year>
                  <publisher-loc>In</publisher-loc>
                  <publisher-name>World Health Organization</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR80">
                <label>80.</label>
                <mixed-citation publication-type="other">Bangladesh Bank. Exchange rate of Taka. Available at: <ext-link ext-link-type="uri" xlink:href="https://www.bb.org.bd/en/index.php/econdata/exchangerate">https://www.bb.org.bd/en/index.php/econdata/exchangerate</ext-link>. Accessed 16 November 2022. [ ].</mixed-citation>
              </ref>
              <ref id="CR81">
                <label>81.</label>
                <mixed-citation publication-type="other">Bangladesh Bank. Current Inflation. Available at: <ext-link ext-link-type="uri" xlink:href="https://www.bb.org.bd/en/index.php/econdata/inflation">https://www.bb.org.bd/en/index.php/econdata/inflation</ext-link>. Accessed 16 November 2022. [ ].</mixed-citation>
              </ref>
              <ref id="CR82">
                <label>82.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Restivo</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Costantino</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Bono</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Maniglia</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Marchese</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Ventura</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Casuccio</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Tramuto</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Vitale</surname>
                      <given-names>F</given-names>
                    </name>
                  </person-group>
                  <article-title>Influenza vaccine effectiveness among high-risk groups: a systematic literature review and meta-analysis of case-control and cohort studies</article-title>
                  <source>Hum Vaccines Immunotherapeutics</source>
                  <year>2018</year>
                  <volume>14</volume>
                  <issue>3</issue>
                  <fpage>724</fpage>
                  <lpage>35</lpage>
                  <pub-id pub-id-type="doi">10.1080/21645515.2017.1321722</pub-id>
                </element-citation>
              </ref>
              <ref id="CR83">
                <label>83.</label>
                <mixed-citation publication-type="other">Organization WH. Global influenza strategy 2019–2030. 2019.</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
